<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS199926</article-id><article-id pub-id-type="doi">10.1101/2024.11.01.621390</article-id><article-id pub-id-type="archive">PPR934777</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The nitrite reductase activity of xanthine oxidoreductase sustains cardiovascular health</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Dyson</surname><given-names>Nicki</given-names></name><degrees>MRes</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Khambata</surname><given-names>Rayomand S.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Parakaw</surname><given-names>Tipparat</given-names></name><degrees>phD</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Massimo</surname><given-names>Gianmichele</given-names></name><degrees>phD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Khuat</surname><given-names>Ngan HH.</given-names></name><degrees>BSc</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Noor</surname><given-names>Annika A.</given-names></name><degrees>BSc</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gee</surname><given-names>Lorna C.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Ivy</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Siddique</surname><given-names>Umme</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sullivan</surname><given-names>Andrew J.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ho</surname><given-names>Jonathan W.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rathod</surname><given-names>Krishnaraj</given-names></name><degrees>PhD, MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barnes</surname><given-names>Michael R.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cabrera</surname><given-names>Claudia P.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ahluwalia</surname><given-names>Amrita</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">+</xref></contrib></contrib-group><aff id="A1"><label>1</label>Barts &amp; The London Faculty of Medicine &amp; Dentistry, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/026zzn846</institution-id><institution>Queen Mary University of London</institution></institution-wrap>, <addr-line>Charterhouse Square</addr-line>, <city>London</city>, <postal-code>EC1M 6BQ</postal-code></aff><aff id="A2"><label>2</label>Department of Pharmacology, Faculty of Dentistry, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01znkr924</institution-id><institution>Mahidol University</institution></institution-wrap>, <country country="TH">Thailand</country></aff><author-notes><corresp id="CR1">
<label>+</label><bold>To whom correspondence should be addressed</bold>: Amrita Ahluwalia, Barts and The London Faculty of Medicine &amp; Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom. Tel: +44 207 882 8377, Fax: +44 207 882 5614, <email>a.ahluwalia@qmul.ac.uk</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>08</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>03</day><month>11</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><sec id="S1"><title>Background</title><p id="P1">Xanthine oxidoreductase (XOR) is a multi-functional enzyme that metabolises purines generating uric acid and is a generator of reactive oxygen species. Both functions have been implicated in the pathogenesis of cardiovascular disease. More recently, a third function of XOR as a nitrite reductase has been identified and been shown to play a key role in the benefits of targeting the non-canonical pathway for nitric oxide (NO) generation in the cardiovascular disease setting. This effect has been specifically attributed to XOR dependent recovery of NO levels. However, whether XOR derived NO plays any role in maintaining cardiovascular homeostasis in health is unknown. To explore this, we used global and hepatocyte-specific <italic>Xdh</italic>-deleted mice to assess cardiovascular homeostasis.</p></sec><sec id="S2"><title>Methods</title><p id="P2"><italic>Xdh</italic><sup>+/+</sup> and <italic>Xdh</italic><sup>+/-</sup>, <italic>Xdh<sup>fl/fl</sup> and Xdh<sup>fl/fl</sup>AlbCre<sup>+/-</sup></italic>(HXOR KO) mice littermates, matched for sex and age, were used for in vivo cardiovascular phenotyping; blood pressure, cardiac function, endothelial reactivity, and leukocyte trafficking. Tissues from these mice were used for biochemical measurements of nitrate, nitrite, and markers of NO downstream signalling.</p></sec><sec id="S3"><title>Results</title><p id="P3"><italic>Xdh</italic><sup>+/-</sup> and HXOR KO mice expressed significantly attenuated liver and plasma nitrite reductase activity and platelet cGMP levels versus littermate controls. These effects were associated with increased systolic blood pressure, left ventricular remodelling, and increased leukocyte activation. These effects were associated with and likely driven by endothelial dysfunction evident in both mouse models. This dysfunction was reflected by increased endothelial adhesion molecule expression (P-selectin), increased ischaemia-induced vasoconstriction, during vessel occlusion, and an impaired flow-mediated dilation response of the iliac artery in vivo.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">In summary, XOR derived NO is critical for maintaining vascular homeostasis under physiological conditions and is key in mediating the benefits of dietary nitrate regimes in cardiovascular pathology</p></sec></abstract><kwd-group><kwd>Hypertension</kwd><kwd>Inflammation</kwd><kwd>Nitrate</kwd><kwd>Nitric oxide</kwd><kwd>Xanthine Oxidoreductase</kwd></kwd-group></article-meta></front><body><sec id="S5" sec-type="intro"><title>Introduction</title><p id="P5">Xanthine oxidoreductase (XOR) is a molybdoflavin enzyme expressed at low level widely but with high expression in the liver<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. Whilst XOR has been localised to the cytoplasm of various cells of the cardiovascular system<sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref></sup> it has also been localised to the extracellular surface. Evidence suggests that this surface expression is derived predominantly from the liver, where hepatocyte-derived XOR is secreted into the circulation from where it then readily binds to the surface of endothelial cells<sup><xref ref-type="bibr" rid="R4">4</xref></sup>, and probably red blood cells (RBCs)<sup><xref ref-type="bibr" rid="R5">5</xref></sup>, via its interaction with glycosaminoglycans (GAGs) on proteoglycans.</p><p id="P6">XOR catalyses the oxidation of hypoxanthine to xanthine and xanthine to uric acid (UA). These reactions generate a flow of electrons from the molybdenum site to the flavin adenine dinucleotide (FAD) site, which in the presence of oxygen results in the production of reactive oxygen species (ROS), namely superoxide (O<sub>2</sub><sup>-</sup>) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). Clinical studies have demonstrated an elevation of XOR activity and expression in patients with hypertension and coronary artery disease<sup><xref ref-type="bibr" rid="R6">6</xref>–<xref ref-type="bibr" rid="R8">8</xref></sup>. In addition, numerous pre-clinical <italic>in vivo</italic> studies have suggested that xanthine oxidase derived ROS are, in part, responsible for the leukocyte recruitment observed in ischaemia reperfusion injury<sup><xref ref-type="bibr" rid="R9">9</xref></sup>. These data suggest that elevated XOR activity and/or expression is pathogenic, although whether this is due to elevated ROS production or elevated UA generation, which has pro-oxidant activity in disease pathologies<sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R11">11</xref></sup>, remains unclear.</p><p id="P7">A hallmark of cardiovascular disease is endothelial dysfunction which is synonymous with a lack of bioavailable nitric oxide (NO), in part, due to scavenging by ROS<sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref></sup>. Whilst XOR is well recognised as a ROS generator, evidence indicates that a third function of the enzyme is its capcity to reduce nitrite to NO<sup><xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R17">17</xref></sup>. This activity has been implicated as a key second step in non-canonical (L-arginine-NO synthase independent) NO generation<sup><xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R19">19</xref></sup>. Briefly, inorganic nitrate, found in green leafy vegetables, enters the circulation, concentrating within the salivary glands. Nitrate-rich saliva is excreted into the oral cavity where it is chemically reduced to nitrite by commensal bacteria expressing nitrate reductases<sup><xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R21">21</xref></sup>. This nitrite-rich saliva once swallowed enters the circulation<sup><xref ref-type="bibr" rid="R22">22</xref></sup> where it is reduced to NO. A number of distinct nitrite reductases have been identified, however there is growing support for the importance of XOR as a nitrite reductase<sup><xref ref-type="bibr" rid="R23">23</xref></sup>. Evidence shows that generation of functional NO via the non-canonical pathway occurs in both health and disease however, whilst XOR has been strongly implicated as an effective NO generator in disease, what role it might play as a nitrite reductase in health is largely unknown. Thus, in this study we investigated the role of XOR-dependent nitrite reductase activity in cardiovascular homeostasis utilising <italic>Xdh</italic> transgenic mice. Additionally, to overcome the lethality of homozygous <italic>Xdh</italic> transgenic mice, the limitations of pharmacological XOR inhibitors and to investigate a proposed primary source of systemic XOR, we generated a unique hepatocyte (Alb-Cre) specific XOR-deletion mouse.</p></sec><sec id="S6" sec-type="methods"><title>Methods</title><p id="P8">For expanded methods see online supplement.</p><sec id="S7"><title>Animal studies</title><p id="P9">All experiments were conducted according to the Animals (Scientific Procedures) Act 1986, United Kingdom, and approved by the UK Home Office.</p></sec><sec id="S8"><title>Generation of <italic>Xdh</italic> global and <italic>Xdh</italic>–hepatocyte specific (HXOR KO) knockout mice</title><p id="P10"><italic>Xdh</italic> knockout mice (<italic>Xdh <sup>-/-</sup></italic>) originally generated by Finkel and colleagues<sup><xref ref-type="bibr" rid="R24">24</xref></sup>, were bred inhouse. Embryos were purchased and rederived at MRC Harwell in C57BL/6J mice and <italic>Xdh<sup>+/-</sup></italic> breeding trios setup. A novel C57BL/6J <italic>Xdh</italic> floxed mouse was generated via CRISPR/Cas9 genome editing (MRC Harwell), and then crossed with C57BL/6J Albumin (Alb) Cre mice (purchased from The Jackson Laboratory) to generate hepatocyte specific XOR KO (HXOR) knockout mice in-house (<xref ref-type="fig" rid="F1">Figure 1 A-B</xref>). Both male and female littermate <italic>Xdh</italic><sup>+/+</sup>, <italic>Xdh</italic><sup>+/-</sup>’<italic>Xdh-</italic><sup>/-</sup> and <italic>Xdh<sup>fl/fi</sup></italic> control / HXOR KO mice were used in all studies.</p></sec><sec id="S9"><title>Dietary nitrate protocol</title><p id="P11">Where required, mice (6 weeks old) were randomly assigned to receive drinking water supplemented with potassium nitrate (KNO<sub>3</sub>, 15 mmol/L) or potassium chloride (KCl, 15 mmol/L, control) for 2 weeks<sup><xref ref-type="bibr" rid="R25">25</xref></sup>. For intravital microscopy studies, mice (3 weeks old) were assigned to the above protocol but for 1 week only.</p></sec><sec id="S10"><title>Tail cuff blood pressure measurement</title><p id="P12">Tail cuff blood pressure (BP) data was collected using the non-invasive CODA mouse BP system (Kent Scientific Corporation, USA) and the acquisition conducted blind to genotype.</p></sec><sec id="S11"><title>Echocardiography</title><p id="P13">Transthoracic echocardiography was performed using a Vevo 3100 imaging system with a MX550D, 40MHz transducer (FujiFilm VisualSonics Inc., Netherlands). Image analysis was conducted offline and blind to genotype<sup><xref ref-type="bibr" rid="R26">26</xref></sup>.</p></sec><sec id="S12"><title>Flow mediated dilation (FMD)</title><p id="P14">FMD of the arteria iliaca externa was visualized using a Vevo 3100 imaging system with a MX550D, 40MHz transducer (FujiFilm VisualSonics Inc., Netherlands). An O-cuff (Kent Scientific Corporation, USA) was placed above the left hind leg knee and inflated to 300 mmHg at T=0 minutes to occlude blood flow through the left arteria iliaca externa. At T=5 minutes the cuff was released and arteria iliaca externa was visualized until T=10 minutes<sup><xref ref-type="bibr" rid="R27">27</xref></sup>. Image analysis was conducted offline and blind to genotype.</p></sec><sec id="S13"><title>Intravital microscopy to determine leukocyte recruitment</title><p id="P15">4-week-old mice were anaesthetised, the mesentery exposed and superfused with bicarbonate-buffered solution (BBS) and leukocyte rolling and adhesion counted as described previously<sup><xref ref-type="bibr" rid="R25">25</xref></sup>.</p></sec><sec id="S14"><title>Flow cytometry</title><p id="P16">Blood was collected and flow cytometry conducted to determine leukocyte subtypes, activation markers and XOR expression. Additionally, bone marrow was isolated and CXCR2 expression determined.</p></sec><sec id="S15"><title>Measurement of nitrate and nitrite levels</title><p id="P17">Plasma and tissue nitrite (NO<sub>2</sub><sup>-</sup>) and nitrate (NO<sub>3</sub><sup>-</sup>) levels (collectively termed NO<sub>x</sub>) were measured using ozone-based chemiluminescence as described previously<sup><xref ref-type="bibr" rid="R25">25</xref></sup>.</p></sec><sec id="S16"><title>Liver homogenate nitrite reductase activity</title><p id="P18">The nitrite reductase activity of liver supernatants was determined using gas-phase chemiluminescence<sup><xref ref-type="bibr" rid="R28">28</xref></sup> at pH 7.4 (representing physiological conditions), pH 6.8 (blood acidosis) and pH 5.5 (severe acidosis - conditions that also favour nitrite reductase pathways).</p></sec><sec id="S17"><title>Immunohistochemistry</title><p id="P19">Liver and heart samples were collected from paraformaldehyde infused mice, sections prepared and stained with H&amp;E, anti-CD62P, anti-CD45 and picrosirius red. Wheat germ agglutinin conjugated to Alexaflour 647 fluorescent staining was conducted in order to determine cardiac myocyte area<sup><xref ref-type="bibr" rid="R26">26</xref></sup>.</p></sec><sec id="S18"><title>Western blotting</title><p id="P20">Equal amounts of protein homogenates of liver were subjected to Western blotting to determine XOR, phosphorylated (p)-eNOS and total eNOS expression levels.</p></sec><sec id="S19"><title>Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)</title><p id="P21">Liver and heart samples were subjected to qPCR and analysed using the comparative threshold cycle (Ct) method (2–ΔΔCt). See <xref ref-type="supplementary-material" rid="SD1">Table S1</xref> for a full list of primers.</p></sec><sec id="S20"><title>RNA sequencing analysis</title><p id="P22">RNA was extracted from cardiac homogenates of global <italic>Xdh<sup>+/+</sup></italic> and <italic>Xdh<sup>+/-</sup></italic>mice and subjected to RNA sequence analysis.</p></sec><sec id="S21"><title>Liver XO activity</title><p id="P23">XO activity of liver homogenates was determined using a commercially available kit, according to manufacturer guidelines (xanthine oxidase assay kit, Abcam, UK).</p></sec><sec id="S22"><title>Pterin-based fluorometric assay of XDH/XO activity</title><p id="P24">To determine the relative proportions of XDH versus XO activity in tissues and plasma we used a modified pterin-based fluorometric assay protocol as previously described<sup><xref ref-type="bibr" rid="R29">29</xref></sup>.</p></sec><sec id="S23"><title>Plasma and urine biochemical analysis</title><p id="P25">Whole blood was obtained via cardiac puncture into a syringe containing 3.8% sodium citrate centrifuged at 14,000 rcf for 5 min at 4 °C and plasma collected. Plasma and spot urine samples were collected at the time of sacrifice, snap frozen and stored at -80°C. Plasma and urine samples were analysed by MRC Harwell Pathology using the AU680 Analyser (Beckman Coulter).</p></sec><sec id="S24"><title>Sample size estimation</title><p id="P26">Preliminary exploratory studies were conducted to assess global KO anion levels and/or BP in age- and sex-matched littermate mice. For these experiments formal sample size estimates were not conducted. For all echocardiography studies, power calculations were based on the sample size required to detect a significant difference in left ventricular (LV) posterior wall thickness. In previous studies, we demonstrated that in mice treated with 2 mg/kg/day Angiotensin II, LV wall thickness in KCl placebo control was 1.3 ± 0.4 mm (mean ± SD), compared to 0.81 ± 0.2 mm in mice treated with KNO<sub>3</sub><sup><xref ref-type="bibr" rid="R26">26</xref></sup>. Using these values, with α = 0.05 and a power of 95%, the required sample size was calculated to be n=12 animals per group. To account for potential technical failures or phenotype-related loss of animals, the sample size was increased to n=15 per group for both mouse models. Tail-cuff BP measurements were also performed in <italic>Xdh<sup>fl/fl</sup></italic> and HXOR KO mice that underwent echocardiography (n = 15). For qPCR, initial assessments of liver TNFα mRNA expression in 4-week-old <italic>Xdh<sup>-/-</sup></italic> mice yielded a relative expression of 1.0 ± 0.66 (mean ± SD), while in <italic>Xdh<sup>+/-</sup></italic>mice, relative expression was 2.0 ± 0.77 (effect size 1.38). Using these values and a power of 95%, a sample size of n=15 mice per group was determined to be sufficient for statistical significance. However, for all qPCR and biochemical analyses, all available samples were utilised, on occasion exceeding n = 15. All groups compared were matched for sex, age, and littermate status.</p></sec><sec id="S25"><title>Statistical and data analysis</title><p id="P27">Data are expressed as mean ± SEM of n mice. Statistical significance was determined using unpaired t-test, one-way ANOVA followed by Dunnett’s post hoc t-test or two-way ANOVA with Sidak’s post-test as required. A P value &lt;0.05 was considered significant. Gaussian distribution and homogeneity of variances of datasets were determined by the Shapiro-Wilk test and Bartlett tests, respectively. For all experiments n values were equal by design however where unequal n values within experiments are shown this relates to technical failure or from identification of outliers using the ROUT<sup><xref ref-type="bibr" rid="R30">30</xref></sup> exclusion test. Where any exclusions have occurred, this has been stated explicitly in the figure legends. All analysis was conducted using GraphPad Prism 10.1.2.</p></sec></sec><sec id="S26" sec-type="results"><title>Results</title><sec id="S27"><title>Biochemical and molecular characterisation of global and liver specific <italic>Xdh</italic> transgenic mice</title><p id="P28">As anticipated, typical numbers of offspring and growth rates were observed in the global <italic>Xdh<sup>+/+</sup> andXdh<sup>+/-</sup></italic> mice, while the <italic>Xdh</italic><sup>-/-</sup> mice had stunted growth with lethality by ~4 weeks of age (<xref ref-type="supplementary-material" rid="SD1">Figure S1A and S1B</xref>)<sup><xref ref-type="bibr" rid="R24">24</xref></sup>. Consequently, samples from <italic>Xdh</italic><sup>-/-</sup> mice were unavailable for non-juvenile (&gt; 4-weeks-old) <italic>in vivo</italic> studies. Whilst weight was similar at 4 and 12 weeks of age, at 20 weeks <italic>Xdh<sup>+/-</sup></italic> mice were modestly heavier than their <italic>Xdh<sup>+/+</sup></italic> littermates (<xref ref-type="supplementary-material" rid="SD1">Figure S1A</xref>). Although when expressed as a change from baseline no statistical differences between <italic>Xdh<sup>+/-</sup></italic> and <italic>Xdh<sup>+/+</sup></italic> were evident. In contrast to the <italic>Xdh</italic><sup>-/-</sup> mice, there were no survival issues observed in the HXOR KO mice compared to control <italic>Xdh<sup>fl/fl</sup></italic> littermates (<xref ref-type="supplementary-material" rid="SD1">Figure S1C</xref>).</p><p id="P29">Global <italic>Xdh</italic> excision in <italic>Xdh</italic><sup>-/-</sup> mice was confirmed by assessment of mRNA (<xref ref-type="supplementary-material" rid="SD1">Figure S1D</xref>) and protein expression (<xref ref-type="fig" rid="F1">Figure 1C, 1D</xref> and <xref ref-type="supplementary-material" rid="SD1">Figure S1F, G</xref>) in several tissues and plasma. In contrast, in HXOR KO mice, <italic>Xdh</italic> mRNA (<xref ref-type="supplementary-material" rid="SD1">Figure S1E</xref>) and XOR protein expression (<xref ref-type="fig" rid="F1">Figure 1I</xref> and <xref ref-type="supplementary-material" rid="SD1">Figure S1H</xref>) were profoundly reduced in the liver only, whilst expression in other organs remained unaltered. HXOR KO mice had a significant but modest reduction of plasma XOR expression, confirming that hepatocyte XOR contributes to circulating plasma XOR levels (<xref ref-type="fig" rid="F1">Figure 1J</xref> and <xref ref-type="supplementary-material" rid="SD1">Figure S1I</xref>).</p><p id="P30">XO activity was significantly reduced in liver homogenates of <italic>Xdh<sup>+/-</sup></italic> mice versus <italic>Xdh<sup>+/+</sup></italic> mice and entirely absent in <italic>Xdh<sup>-/-</sup></italic> mice, (<xref ref-type="fig" rid="F1">Figure 1E</xref>). Similarly, XO activity was reduced in HXOR KO mice in comparison to the <italic>Xdh<sup>fl/l</sup></italic> mice (<xref ref-type="fig" rid="F1">Figure 1K</xref>). Interestingly, whilst an allele dependent reduction in plasma UA levels was evident in the global deletion mice (<xref ref-type="fig" rid="F1">Figure 1F</xref>) no such effect was observed in HXOR KO mice (<xref ref-type="fig" rid="F1">Figure 1L</xref>). Assessment of XDH and XO proportions in liver samples demonstrated an equivalent decrease in activity for both isoforms in the global deletion mice (<xref ref-type="fig" rid="F1">Figure 1G</xref>), with similar reductions in plasma XDH and XO levels in <italic>Xdh<sup>+/-</sup></italic> mice (<xref ref-type="fig" rid="F1">Figure 1H</xref>). In contrast, although a complete ablation of XDH and XO activity was evident in liver samples of HXOR KO mice (<xref ref-type="fig" rid="F1">Figure 1M</xref>), only a modest reduction in plasma activity was evident, which did not reach statistical significance (<xref ref-type="fig" rid="F1">Figure 1N</xref>).</p><p id="P31">The reductions in XOR expression were not associated with any overt changes in general circulating biochemical parameters measured in 4-week-old global KO mice and 20-week old HXOR KO mice, except for urea levels which were reduced in the global <italic>Xdh<sup>+/-</sup></italic> mice, but not evident in the liver-selective deleted mice (<xref ref-type="supplementary-material" rid="SD1">Table S2</xref>) aligning with previous observations<sup><xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup>. Importantly, neither <italic>Xdh<sup>+/</sup></italic> or HXOR KO mice expressed differences in markers of liver damage, including ALP, AST and ALT, compared to their wild type controls (<xref ref-type="supplementary-material" rid="SD1">Table S2</xref>).</p></sec><sec id="S28"><title><italic>Xdh</italic> deletion alters nitrite reductase activity and influences nitrite and nitrate dynamics</title><p id="P32">To explore whether <italic>Xdh</italic> deletion impacts circulating nitrite and nitrate levels, we measured both anions in tissues and blood of mice of ~4 weeks of age to enable comparisons between <italic>Xdh<sup>+/+</sup></italic>, <italic>Xdh<sup>+/-</sup></italic> and <italic>Xdh<sup>-/-</sup></italic> littermate mice. We observed an allele-dependent elevation in liver and plasma nitrite and nitrate levels in globally deficient mice (<xref ref-type="fig" rid="F2">Figure 2A-D</xref>). These changes were associated with an allele-dependent decrease in nitrite reductase activity at pH 7.4 and 6.8 in liver homogenates and plasma (<xref ref-type="fig" rid="F2">Figure 2I–K</xref>). Interestingly, in comparison to <italic>Xdh<sup>fl/fl</sup></italic> mice, HXOR KO mice expressed an increase in liver nitrate levels at 20 weeks (<xref ref-type="fig" rid="F2">Figure 2F</xref>) corresponding with a decrease in plasma nitrite levels (<xref ref-type="fig" rid="F2">Figure 2G</xref>). The age-dependent changes in anion levels, in the HXOR KO mice, were also associated with reduced nitrite-reductase activity in both liver and plasma in 20-week-old mice (<xref ref-type="fig" rid="F2">Figure 2M-O</xref>). To determine whether the reductions in nitrite reductase activity led to deficiencies in vascular NO, we assessed platelet cGMP levels as a marker of NO activity. Indeed, in both the <italic>Xdh<sup>-/-</sup></italic> and HXOR KO mice platelet cGMP was reduced in comparison to control littermate mice, <italic>Xdh<sup>+/+</sup></italic>and <italic>Xdh<sup>m</sup></italic> mice respectively, although this did not reach statistical significance in HXOR KO mice (<xref ref-type="fig" rid="F2">Figure 2L and P</xref>).</p><p id="P33">There is some suggestion that in the absence of functional XOR, compensatory changes may occur in eNOS expression and/or activity. To assess whether changes in eNOS might account for the above noted effects we assessed total eNOS mRNA (<xref ref-type="supplementary-material" rid="SD1">Figure S2A and S2B</xref>) and protein expression (<xref ref-type="supplementary-material" rid="SD1">Figure S2D</xref>, <xref ref-type="supplementary-material" rid="SD1">S2F</xref>, <xref ref-type="supplementary-material" rid="SD1">S2G</xref> and <xref ref-type="supplementary-material" rid="SD1">S2I</xref>), as well as phospho-eNOS expression (<xref ref-type="supplementary-material" rid="SD1">Figure S2E</xref> and <xref ref-type="supplementary-material" rid="SD1">S2H</xref>) as a measure of activity, in liver homogenates. We found no evidence of differences in the <italic>Xdh<sup>-/-</sup></italic> and HXOR KO mice versus the control littermate <italic>Xdh<sup>+/+</sup></italic> and <italic>Xdh<sup>fl/fl</sup></italic> mice respectively.</p></sec><sec id="S29"><title>Hepatocyte <italic>Xdh</italic> deletion elevates BP and promotes cardiac remodelling</title><p id="P34">Since there is substantial evidence indicating that the non-canonical pathway for NO delivery can profoundly influence BP we measured BP in both mouse models over 24 weeks. However, since <italic>Xdh<sup>-/-</sup></italic> die at ~4 weeks of age, only <italic>Xdh<sup>+/+</sup></italic> and <italic>Xdh<sup>+/-</sup></italic> mice were available. At 4 weeks of age <italic>Xdh<sup>+/+</sup></italic> and <italic>Xdh<sup>+/-</sup></italic> mice exhibited comparable BP. However, in agreement with previous findings<sup><xref ref-type="bibr" rid="R30">30</xref></sup> between 8-24 weeks of age <italic>Xdh<sup>+/-</sup></italic> mice exhibited elevated systolic BP (SBP), diastolic BP (DBP) and mean arterial pressure (MAP) versus litter and age-matched <italic>Xdh<sup>+/+</sup></italic> mice (<xref ref-type="fig" rid="F3">Figure 3A-C</xref>). Importantly, this phenotype was replicated in mice with hepatocyte selective deletion of <italic>Xdh,</italic> with HXOR KO mice expressing elevated SBP, DBP and MAP from 10 weeks of age (<xref ref-type="fig" rid="F3">Figure 3D-F</xref>).</p><p id="P35">Since the BP phenotype was evident between 8-10 weeks, we conducted echocardiography from this timepoint onwards. Overall, <xref ref-type="fig" rid="F4">Figure 4</xref> demonstrates that <italic>Xdh<sup>+/-</sup></italic> mice develop significant LV hypertrophy (<xref ref-type="fig" rid="F4">Figure 4A</xref>), at 16 weeks of age, following the onset of hypertension. The LV diastolic volume (<xref ref-type="fig" rid="F4">Figure 4B</xref>) and area (<xref ref-type="fig" rid="F4">Figure 4E</xref>) are significantly enlarged however, the diastolic internal diameter of the LV (<xref ref-type="fig" rid="F4">Figure 4F</xref>) is not affected. This LV hypertrophy is accompanied by significant thickening of the LV posterior wall (<xref ref-type="fig" rid="F4">Figure 4I</xref>) in <italic>Xdh<sup>+/-</sup></italic> mice. No significant changes in LV systolic parameters were observed in <italic>Xdh<sup>+/-</sup></italic> mice in either the short axis (<xref ref-type="supplementary-material" rid="SD1">Figure S3</xref>) or parasternal long axis (<xref ref-type="supplementary-material" rid="SD1">Figure S4</xref>). This compensatory LV diastolic wall thickening in <italic>Xdh<sup>+/-</sup></italic> mice likely prevents a reduction in ejection fraction (<xref ref-type="fig" rid="F4">Figure 4M</xref>) and stroke volume (<xref ref-type="fig" rid="F4">Figure 4N</xref>), resulting in <italic>Xdh<sup>+/-</sup></italic> mice having a cardiac output (<xref ref-type="fig" rid="F4">Figure 4Q</xref>) comparable to that of <italic>Xdh<sup>+/+</sup></italic> littermates.</p><p id="P36">Similarly, HXOR KO mice display significant LV hypertrophy coinciding with the onset of hypertension (<xref ref-type="fig" rid="F4">Figure 4C</xref>). However, in contrast to the global KO model, the remodelling in HXOR KO mice appeared to be less compensatory and more maladaptive. HXOR KO mice displayed a trend of reduced LV volume (<xref ref-type="fig" rid="F4">Figure 4D</xref>) and area (<xref ref-type="fig" rid="F4">Figure 4G</xref>) in both diastole and systole (<xref ref-type="supplementary-material" rid="SD1">Figure S6</xref>), which corresponds to a significant decrease in total LV volume (<xref ref-type="supplementary-material" rid="SD1">Figure S6H</xref>) and area (<xref ref-type="supplementary-material" rid="SD1">Figure S6F</xref>). This smaller LV area is attributed to a significant reduction in the diastolic internal diameter (<xref ref-type="fig" rid="F4">Figure 4H</xref>). The reduced internal diameter in HXOR KO mice may be due to significant thickening of both the posterior (<xref ref-type="fig" rid="F4">Figure 4K</xref> and <xref ref-type="supplementary-material" rid="SD1">S5K</xref>) and anterior walls (<xref ref-type="supplementary-material" rid="SD1">Figures S5E</xref> and <xref ref-type="supplementary-material" rid="SD1">S5F</xref>). The pathological LV remodelling and reduced internal diameter in HXOR KO mice did not affect heart rate (<xref ref-type="fig" rid="F4">Figure 4L</xref>) or ejection fraction (<xref ref-type="fig" rid="F4">Figure 4O</xref>) but did significantly attenuate LV stroke volume (<xref ref-type="fig" rid="F4">Figure 4P</xref>), which in HXOR KO mice corresponds with a decreased cardiac output (<xref ref-type="fig" rid="F4">Figure 4R</xref>). To further assess LV mass, excised LVs were collected and weighed from 20-week-old HXOR KO and <italic>Xdh<sup>fl/fl</sup></italic>littermate mice. <xref ref-type="fig" rid="F4">Figure 4S</xref> demonstrates that, in accordance with the echocardiographic data, the LV mass normalised to the tibia length of HXOR KO mice is significantly larger than the wild type controls (<xref ref-type="fig" rid="F4">Figure 4S</xref>).</p><p id="P37">Further assessment of diastolic function in HXOR KO mice revealed no single parameter showing a statistically significant change. However, a trending increase in the E/E’ ratio (<xref ref-type="supplementary-material" rid="SD1">Figure S8H</xref>), LV myocardial performance index (MPI) using isovolumetric parameters (IV) (<xref ref-type="supplementary-material" rid="SD1">Figure S8I</xref>), and LV MPI using non-filling time (NFT) (<xref ref-type="supplementary-material" rid="SD1">Figure S8J</xref>) were evident. The impaired cardiac output in HXOR KO mice also corresponds with a trend towards reduced aortic velocity time integral (VTI) (<xref ref-type="supplementary-material" rid="SD1">Figure S9A</xref>) relative to their littermate controls.</p><p id="P38">Since <italic>in vivo</italic> functional studies suggested BP-induced changes in cardiac function occurred as early as 8 weeks of age and increased thereafter, we measured immunohistochemical markers of hypertrophy and/or fibrosis at both 8 and 20 weeks of age. At 8-weeks of age <italic>Xdh<sup>+/+</sup></italic> and <italic>Xdh<sup>+/-</sup></italic>mice expressed comparable collagen content and cardiomyocyte area (<xref ref-type="fig" rid="F5">Figure 5B and C</xref>), and a similar pattern was also observed in 8-week-old HXOR KO mice vs <italic>Xdh<sup>fm</sup></italic> (<xref ref-type="fig" rid="F5">Figure 5D and E</xref>). However, in 20-week-old HXOR KO mice when both raised BP and cardiac dysfunction are strongly expressed, elevated collagen deposition was observed within the heart (<xref ref-type="fig" rid="F5">Figure 5D</xref>) associated with a trend towards increased cardiomyocyte area (<xref ref-type="fig" rid="F5">Figure 5E</xref>).</p><p id="P39">To explore the potential signalling pathways that might drive these effects we conducted bulk RNA sequencing of cardiac homogenates of 4-week-old mice to better explore the initiating signalling pathways triggered by an absence of <italic>Xdh.</italic> Our analyses demonstrate an upregulation of pro-fibrotic pathways in the young <italic>Xdh<sup>+/</sup></italic> mice, indicative of the triggering of cardiac remodelling compared to their <italic>Xdh<sup>+/+</sup></italic> littermate controls (<xref ref-type="fig" rid="F5">Figure 5F and G</xref>). Accordingly, qPCR of key cardiac pro-fibrotic signalling pathways at 4-20 weeks suggested some (albeit modest) activation of the TGFβ-SMAD-Col1a pathway with a trend to increase in TGFβ expression in the 4-week-old <italic>Xdh<sup>+/-</sup></italic> mice and increased Col1a at 8 weeks (<xref ref-type="fig" rid="F5">Figure 5H-K</xref>) with evidence of upregulated SMAD2-3 in the HXOR KO mice relative to their <italic>Xdh<sup>fl/fl</sup></italic> littermates (<xref ref-type="fig" rid="F5">Figure 5L-O</xref>). These findings hint at the suggestion that any pro-fibrotic effects in the heart were likely due to an absence of circulating XOR rather than XOR expressed in cardiac cells. Collectively these data add further support to the view that impaired liver XOR-dependent nitrite reductase activity in HXOR KO mice results in a phenotype resembling that of early heart failure with a preserved ejection fraction (HFpEF).</p></sec><sec id="S30"><title>Reduced hepatic nitrite reductase activity leads to systemic inflammation and endothelial dysfunction</title><p id="P40">Interestingly, bulk RNA seq analyses of whole heart homogenates also highlighted the upregulation of pro-inflammatory signalling pathways in <italic>Xdh<sup>+/-</sup></italic>mice (<xref ref-type="fig" rid="F5">Figure 5G</xref>). To explore this further we conducted qPCR of cardiac supernatants in both the <italic>Xdh<sup>+/-</sup></italic> and HXOR KO mice relative to their littermate controls for a range of proinflammatory mediators (<xref ref-type="supplementary-material" rid="SD1">Figure S10</xref> and <xref ref-type="supplementary-material" rid="SD1">S11</xref>). These results reveal mild upregulation of pro-inflammatory mediators in the hearts of aging HXOR KO mice, particularly TNFα (<xref ref-type="supplementary-material" rid="SD1">Figure S10G and S11G</xref>).</p><p id="P41">In cardiovascular disease, systemic inflammation drives endothelial dysfunction that often precedes cardiac dysfunction. Endothelial NO deficiency plays a critical role in this process. Therefore, we assessed endothelial function <italic>in vivo</italic>. As expected, cuff inflation to occlude the external iliac artery followed by cuff release, led to a prominent increase in vessel diameter due to shear stress-induced endothelial activation in control <italic>Xdh<sup>+/+</sup></italic> mice (<xref ref-type="fig" rid="F6">Figure 6A</xref>). Interestingly, whilst there was minimal change in the vessel diameter during the occlusion period (1-5 min) in <italic>Xdh<sup>+/+</sup></italic> mice, in <italic>Xdh<sup>+/-</sup></italic> mice there was a significant decrease in vessel diameter (<xref ref-type="fig" rid="F6">Figure 6B</xref>). After cuff release, <italic>Xdh<sup>+/-</sup></italic> mice demonstrated significantly reduced vessel dilation compared to<italic>Xdh<sup>+/+</sup></italic> mice (<xref ref-type="fig" rid="F6">Figure 6A and C</xref>). In HXOR KO mice a similar response profile to both occlusion (vasoconstriction) and shear stress (reduced FMD) relative to their littermate controls was observed (<xref ref-type="fig" rid="F6">Figure 6D-F</xref>). These findings suggest that hepatocyte XOR plays a crucial role in maintaining systemic endothelial function and blood flow.</p></sec><sec id="S31"><title>XOR-deficiency triggers hepatic inflammation driving systemic inflammation and endothelial dysfunction</title><p id="P42">Since the mild inflammatory effects were observed in both the liver-specific knockout and the globally deleted mice, we hypothesized that the cardiac dysfunction and mild inflammation in the heart might be secondary to a systemic inflammation that originated within the liver of these animals. qPCR analyses of key inflammatory mediators revealed increased mRNA expression of TNFα, particularly at young ages, in the liver of both <italic>Xdh<sup>+/-</sup></italic> (<xref ref-type="fig" rid="F7">Figure 7A</xref>) and HXOR KO mice relative to their wild type littermates (<xref ref-type="fig" rid="F7">Figure 7C</xref>). We confirmed these changes in TNFα expression in the plasma of 4-week-old <italic>Xdh<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="F7">Figure 7B</xref>) and a trend to increase in 20-week-old HXOR KO mice (<xref ref-type="fig" rid="F7">Figure 7D</xref>). No statistically significant alterations were observed in other surveyed inflammatory mediators, except for NLRP-1 and TLR5 in HXOR KO mice (<xref ref-type="supplementary-material" rid="SD1">Figures S12</xref>, <xref ref-type="supplementary-material" rid="SD1">S13</xref>, and <xref ref-type="supplementary-material" rid="SD1">S14</xref>x).</p><p id="P43">Confirmation of the functional impact of an increased systemic inflammatory state and dysfunctional endothelium was obtained from intra-vital microscopy studies. In 4–5-week-old mice, leukocyte rolling was enhanced in <italic>Xdh<sup>+/-</sup></italic> compared to <italic>Xdh<sup>+/+</sup></italic> mice (<xref ref-type="fig" rid="F7">Figure 7E</xref>), while leukocyte adhesion remained comparable between the groups (<xref ref-type="fig" rid="F7">Figure 7F</xref>). Similarly, HXOR KO mice exhibited increased leukocyte rolling (<xref ref-type="fig" rid="F7">Figure 7G</xref>) with no change in adhesion (<xref ref-type="fig" rid="F7">Figure 7H</xref>) relative to the <italic>Xdh<sup>fl/fl</sup></italic> littermates.</p><p id="P44">Interestingly, there were no observed differences in the number of CD45+ cells within the liver or heart of 8 or 20-week-old <italic>Xdh<sup>+/-</sup></italic> or HXOR KO mice (<xref ref-type="supplementary-material" rid="SD1">Figure S15</xref> and <xref ref-type="supplementary-material" rid="SD1">S16</xref>). However, indicative of a nascent pro-inflammatory state and emerging cardiac dysfunction due to deficient NO generation, there was an increase in the expression of the NO-sensitive endothelial adhesion molecule CD62P (P-selectin) in endothelial cells of both the liver and heart of <italic>Xdh<sup>+/-</sup></italic> and HXOR KO mice (<xref ref-type="fig" rid="F7">Figure 7J-M</xref>). That the enhanced leukocyte rolling is due primarily to changes in endothelial activity rather than direct changes in leukocyte activity is supported by the lack of difference in circulating leukocyte number (<xref ref-type="supplementary-material" rid="SD1">Table S4</xref>) or activation state (<xref ref-type="supplementary-material" rid="SD1">Table S5</xref>) between <italic>Xdh<sup>+/-</sup></italic>and <italic>Xdh<sup>+/+</sup></italic> mice. These findings suggest the pivotal role of hepatocyte-derived XOR in triggering hepatic inflammation that initiates a systemic pro-inflammatory response leading to generalised endothelial dysfunction, elevated BP, and ultimately cardiac remodelling.</p></sec><sec id="S32"><title><italic>Xdh</italic> deletion prevents dietary nitrate-induced protection against ischaemia-reperfusion injury</title><p id="P45">We investigated the impact of XOR deletion on ischaemia/reperfusion (I/R) injury-induced leukocyte activation and recruitment, given the previous implication of XOR in this response. As expected <italic>Xdh<sup>+/+</sup></italic> mice exhibited elevated levels of leukocyte rolling (<xref ref-type="fig" rid="F8">Figure 8A</xref>) and adhesion (<xref ref-type="fig" rid="F8">Figure 8B</xref>) in response to I/R injury compared to basal conditions. However, these effects were absent in <italic>Xdh<sup>+/-</sup></italic> mice, with only a small elevation in leukocyte adhesion observed under I/R injury conditions (<xref ref-type="fig" rid="F8">Figure 8A and B</xref>). These findings suggest that while XOR is protective under physiological conditions, it contributes to leukocyte recruitment during I/R injury. In addition, in <italic>Xdh<sup>+/+</sup></italic> mice, treatment with inorganic nitrate intervention resulted in a trend to reduction in I/R-induced leukocyte rolling (<xref ref-type="fig" rid="F8">Figure 8C</xref>) with no change in adhesion (<xref ref-type="fig" rid="F8">Figure 8D</xref>). In contrast this intervention had no effect in <italic>Xdh<sup>+/-</sup></italic> mice. Analysis of circulating leukocyte numbers in mice supplemented with inorganic nitrate showed a statistically significant reduction in neutrophil and inflammatory monocyte counts in <italic>Xdh<sup>+/+</sup></italic> mice, which was attenuated in <italic>Xdh<sup>+/-</sup></italic> mice, with no changes observed in other leukocyte subtypes (<xref ref-type="supplementary-material" rid="SD1">Table S6</xref>). To assess if this was due to neutrophil mobilisation, as a surrogate for this we assessed CXCR2 expression on circulating and bone marrow neutrophils and inflammatory monocytes, finding no significant changes with inorganic nitrate treatment (<xref ref-type="supplementary-material" rid="SD1">Table S7</xref>). Moreover, the expression of CD162, CD62L and CD11b on various leukocyte populations remained unaltered with inorganic nitrate intervention (<xref ref-type="supplementary-material" rid="SD1">Table S8</xref>). Collectively, these data suggest that XOR plays a functional role in mediating leukocyte recruitment under physiological conditions and may also help attenuate I/R-induced leukocyte recruitment in the presence of increased circulating nitrite.</p><p id="P46">Given the observed modulation in leukocyte recruitment, both at baseline and following nitrate intervention, we also investigated whether circulating leukocytes express XOR. We did not detect extracellular XOR expression on any leukocyte subtype in <italic>Xdh<sup>+/+</sup></italic> or <italic>Xdh<sup>+/-</sup></italic>mice (<xref ref-type="supplementary-material" rid="SD1">Table S9</xref>). In contrast, intracellular XOR expression was detected in all leukocyte subtypes assessed, albeit with varying degrees of expression (<xref ref-type="supplementary-material" rid="SD1">Table S9</xref>). In <italic>Xdh<sup>+/+</sup></italic> mice, neutrophils exhibited the greatest level of XOR expression, followed by monocytes, lymphocytes and B cells. In <italic>Xdh<sup>+/-</sup></italic> mice, a similar expression profile was observed, albeit the level of XOR expression in neutrophils was significantly reduced. These data suggest that leukocytes, in particular neutrophils, have the capacity to synthesise XOR, implying their ability to reduce nitrite to NO.</p></sec></sec><sec id="S33" sec-type="conclusions"><title>Conclusion</title><p id="P47">Herein, we demonstrate a critical role for hepatic XOR mediated bioconversion of nitrite to NO in maintaining vascular and cardiac health. This XOR-derived NO suppresses leukocyte activation, maintains healthy BP and cardiac function. We also demonstrate that XOR may be harnessed to reduce leukocyte activation in conditions such as I/R injury by altering the balance of XOR substrate availability in favour of NO production, through elevation of circulating nitrite levels. Collectively these findings implicate liver-derived XOR in sustaining cardiovascular physiology and, moreover, challenge the view that the function of XOR in the cardiovascular system is solely one of driving disease pathology<sup><xref ref-type="bibr" rid="R31">31</xref>–<xref ref-type="bibr" rid="R33">33</xref></sup>. Moreover, these findings highlight the potential in targeting hepatic XOR through dietary nitrate delivery to prevent vascular damage by attenuating the systemic inflammation that drives vascular dysfunction and cardiovascular disease.</p><p id="P48">Using the global <italic>Xdh</italic> deletion mouse model<sup><xref ref-type="bibr" rid="R24">24</xref></sup> we confirmed previous observations indicating that reduced expression of XOR leads to reductions in the products of its activity i.e. UA and O<sub>2</sub><sup>-</sup>/ H<sub>2</sub>O<sub>2</sub>. However, in addition we show, for the first time, that this expected reduction in redox activity is accompanied by a clear allele-dependent reduction in nitrite reductase activity in tissues and blood, also reflected by alterations in nitrite and nitrate levels. Using the pterin fluorometric assay, we observed a greater proportion of XOR in the XDH form, vs XO, in the liver, whilst in plasma the proportions were comparable. This difference has been attributed previously to sulfhydryl oxidation once released into the circulation <sup><xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R34">34</xref></sup>. Since we identified nitrite reductase activity in both the liver and plasma, this observation suggests that both isoforms likely contribute to physiological levels of NO, despite some suggestions that this is not the case<sup><xref ref-type="bibr" rid="R35">35</xref></sup>.</p><p id="P49">To further explore the role of XOR-derived NO in cardiovascular function we created a floxed mouse, using a CRISPR-Cas9 approach, to overcome the difficulties associated with global deletion <sup><xref ref-type="bibr" rid="R36">36</xref></sup>. We focussed specifically upon deletion of hepatocyte <italic>Xdh</italic> since the liver is a primary source of circulating XOR implicated in driving the pathogenesis of cardiovascular disease<sup><xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R37">37</xref></sup>. This mouse is different from the recently published mouse model created by Kelley and co-workers using a Neo cassette approach<sup><xref ref-type="bibr" rid="R38">38</xref></sup>. Basic phenotyping of XOR expression and activity confirmed selective hepatic deletion and showed considerable similarity with the previously published mouse model. However, some important differences between the models were identified. Whilst in the previous study an approximate 50-60% reduction in plasma XOR activity was evident<sup><xref ref-type="bibr" rid="R38">38</xref></sup>, in this CRISPR-Cas9-induced deletion mouse this was not the case; a finding further supported by our observations that there was no significant change in plasma UA level. This discrepancy between the models may relate to the method used to quantify XOR activity, perhaps off-target deletion, but also possibly due to the method for blood collection. We collected blood using citrate as an anticoagulant to prevent heparin-mediated scavenging of GAG bound XOR found on RBCs or endothelial cells<sup><xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R39">39</xref></sup>. Indeed, our analysis shows that XOR expression was unaffected in other tissues collected from the HXOR KOs versus the littermate controls indicating hepatocyte selectivity. But we also suggest that, in addition to the liver, circulating XOR levels may arise from release by other high XOR-expressing organs, such as for instance the lung or adipose tissue, and thus compensating, at least in part, for the absence of liver-derived circulating XOR<sup><xref ref-type="bibr" rid="R40">40</xref></sup>, at least in this knockout setting.</p><p id="P50">In the HXOR KO mice, we identified alterations in NO<sub>x</sub> levels with a rise particularly in nitrate levels in the liver. We suggest that the elevation in liver and plasma nitrite and nitrate, in both models, is due to reduced XOR-dependent conversion of nitrite to NO. We speculate that this leads to an accumulation of plasma nitrite due to less utilisation/metabolism. Nitrite has a short half-life, primarily due to its oxidation to nitrate, and the rise in nitrate levels likely reflects re-direction of nitrite down this route of metabolism<sup><xref ref-type="bibr" rid="R41">41</xref>,<xref ref-type="bibr" rid="R42">42</xref></sup>. We also speculate that the attenuation of plasma nitrite in the HXOR KO animals is associated with decreased systemic NO bioavailability and oxidation into nitrite since we demonstrate clear reductions in the levels of platelet cGMP. It is noteworthy that in the <italic>Xdh</italic><sup>-/-</sup> animals renal function declines rapidly as they age due to the build-up of purine crystals in the kidney<sup><xref ref-type="bibr" rid="R24">24</xref></sup>,<sup><xref ref-type="bibr" rid="R36">36</xref></sup>, and thus it is possible that disordered renal clearance contributes in some way to the alterations of NOx levels. However, since there is no evidence for renal dysfunction/failure in either the global heterozygotes or those with selective hepatocyte deletion, it is unlikely that failure of renal clearance underlies the changes seen. These findings support the suggestion that hepatocyte XOR is not the exclusive source of circulating physiological XOR, and that XOR released from other organs into the circulation express nitrite reductase activity. These studies also support the many <italic>in vitro</italic> observations implicating XOR, using pharmacological inhibitors i.e. allopurinol and febuxostat, demonstrating nitrite reductase activity in tissues collected primarily from ‘cardiovascular disease’ scenarios in both experimental animals and patients (for review<sup><xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R43">43</xref></sup>). Herein, we now demonstrate that, in contrast to some recent suggestions<sup><xref ref-type="bibr" rid="R44">44</xref></sup>, in addition to acting as a nitrite reductase in disease, that the nitrite reductase activity of XOR activity also plays an important role in physiology.</p><p id="P51">Due to the critical role of vascular NO in BP control, we assessed whether XOR deletion influences BP. Both models displayed increasing BP with age versus their respective littermate controls, despite normal BP at 4 weeks. This is in accord with a previous study showing modest SBP elevation at 2 months in <italic>Xdh<sup>+/-</sup></italic> mice, increasing at 4 and 18 months<sup><xref ref-type="bibr" rid="R30">30</xref></sup>. Importantly, in our hands this raised BP was associated with endothelial dysfunction; as reflected by impaired FMD response. Since this effect was in the absence of circulating UA changes but was associated with decreased systemic XOR nitrite reductase activity and NO bioavailability, and since reduced endothelium-derived NO bioavailability<sup><xref ref-type="bibr" rid="R45">45</xref>,<xref ref-type="bibr" rid="R46">46</xref><xref ref-type="bibr" rid="R47">47</xref></sup> is thought to underlie this effect, we suggest that the hypertension observed in the genetic models is attributed to decreased circulating liver-derived XOR-dependent NO generation at the level of the endothelium.</p><p id="P52">The mechanism by which XOR influences vascular tone and thus BP has long been debated but remains uncertain. Hyperuricemia has been associated with hypertension<sup><xref ref-type="bibr" rid="R47">47</xref></sup>, however, in 1 contrast, a recent study has suggested that plasma XOR activity, not serum UA, is positively) associated with BP<sup><xref ref-type="bibr" rid="R49">49</xref></sup>. Additionally, whilst lower levels of oxidative stress were associated) with BP, this association was absent at higher oxidative stress levels<sup><xref ref-type="bibr" rid="R48">48</xref></sup>. There are also meta-analyses suggesting that XOR inhibition lowers BP<sup><xref ref-type="bibr" rid="R49">49</xref></sup>. But it should be noted that there are also studies showing no effect on bp<sup><xref ref-type="bibr" rid="R50">50</xref>,<xref ref-type="bibr" rid="R51">51</xref></sup>. Collectively, these observations highlight the current confusion regarding the role of XOR on BP. We suggest that this complexity arises from a lack of consideration of the full spectrum of XOR activity. Our data demonstrates that a single allele deletion of <italic>Xdh</italic> results in an elevation of BP, contrasting with suggestions that pharmacological XOR inhibition results in a small but significant lowering of BP in certain patient cohorts<sup><xref ref-type="bibr" rid="R52">52</xref>,<xref ref-type="bibr" rid="R53">53</xref></sup>. A potential explanation for these conflicting data is that inhibition of XOR will result in a lowering of UA and ROS production but also a loss of XOR mediated nitrite reduction. It has been suggested that in a scenario where conventional endothelial NO generation is prevented, i.e. the eNOS KO mouse, that there is a compensatory rise in XOR activity, to restore NO bioavailability<sup><xref ref-type="bibr" rid="R54">54</xref></sup>. This could lead to speculation that any apparent changes in levels of NO or its metabolites may be related to alterations in other sources of NO<sup><xref ref-type="bibr" rid="R55">55</xref></sup>. This possibility, however, is unlikely in the current setting since neither eNOS nor phospho-eNOS expression were altered in either genetic model.</p><p id="P53">Interestingly, our findings also suggest that the normal response of the endothelium to blood flow is, at least in part, dependent upon vascular nitrite reductase activity of XOR. Indeed, occlusion of the iliac artery resulted in pronounced vasoconstriction in XOR-deletion mice, an effect not observed in wild-type controls of either genotype. This indicates that vascular XOR activity is regulated by shear stress and suggests that, under conditions of reduced oxygen tension (which enhances XOR-derived nitrite reductase activity<sup><xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R28">28</xref></sup> but impairs eNOS-derived NO generation due to its oxygen dependence<sup><xref ref-type="bibr" rid="R54">54</xref></sup>), XOR compensates by delivering NO. Importantly, we also show that this XOR dependency relates to liver-derived, and likely, endothelial bound, XOR using the HXOR KO mice. Recently, Cortese-Krott and co-workers, demonstrated that the FMD response of the iliac artery is completely absent in endothelial cell specific eNOS-ablated mice. However, these mice did not show any evidence of enhanced vasoconstriction with occlusion<sup><xref ref-type="bibr" rid="R27">27</xref></sup>. We speculate that upregulation of XOR-dependent nitrite reductase activity in the low oxygen environment underlies this effect. Indeed, there is evidence that eNOS and XOR operate in tandem to ensure vascular NO delivery, and that in the absence of eNOS there is a compensatory increase in XOR-dependent NO generation to maintain vascular homeostasis<sup><xref ref-type="bibr" rid="R54">54</xref></sup>.</p><p id="P54">Prolonged elevated BP impacts cardiac function, and indeed, in the global deletion mice, raised BP precedes the cardiac phenotype. However, in HXOR KO mice, we observed a reduction in cardiac output alongside increased left ventricular posterior wall (LVPW) thickening and decreased left ventricular internal diameter (LVID). The disparity in cardiac phenotypes—compensatory LV hypertrophy in the global heterozygous KO model, versus maladaptive remodelling in the homozygous hepatocyte KO model, likely highlights the distinct role of hepatocyte-derived XOR in cardiovascular homeostasis. The HXOR KO mice developed maladaptive cardiac -remodelling as early as 6 weeks of age, before the apparent onset of hypertension, indicating a potential BP-independent component. Indeed, our previous studies<sup><xref ref-type="bibr" rid="R26">26</xref></sup> have identified both BP-dependent and independent pathways underlying beneficial effects of activating the non-canonical pathway, through dietary nitrate delivery, in the setting of a severe cardiac dysfunction phenotype. Both pathways are dependent upon NO activity, but the latter is mediated by NO-driven suppression of the TGFβ-SMAD-Col1a pathway of fibrosis. Indeed, this latter possibility likely explains, at least a component of the effects, since upregulated mRNA expression for both TGFβ and Col1a were evident in the hearts of both <italic>Xdh</italic>-deficient models. Importantly, the cardiac changes, in both models, are consistent with a heart failure phenotype with diastolic dysfunction. These observations are in contradiction to a recent study using the Neo cassette approach to hepatic XOR deletion, where no differences in LV structure or function in comparison to <italic>Xdh fi/fi</italic> mice were observed<sup><xref ref-type="bibr" rid="R38">38</xref>,<xref ref-type="bibr" rid="R56">56</xref></sup>. The reason for this discrepancy may relate to the use of a mixed-age population of mice, power of the study and to the sex utilised in the Kelley study. In the aforementioned study, mice were 6-13 weeks old, with an n-number (n=7) and only male mice were used. Our study used equal numbers of male and female mice and aged-matched littermates, as well as assessment of a time-course exposing important age-dependent changes<sup><xref ref-type="bibr" rid="R57">57</xref></sup>.</p><p id="P55">Mechanistically, our findings link the XOR-dependent vascular dysfunction temporally with inflammation. Within the liver, heart and plasma we saw consistent elevations in one of the early cytokine signals in the inflammatory response i.e. TNFα. These differences overall appeared to increase with age, particularly in the HXOR KO, but also appeared to follow a temporal pattern that begins in early age with rises in the cytokine in the liver, then plasma and then the heart. We suggest that the removal of <italic>Xdh</italic> from the liver eliminates an NO-mediated brake-mechanism leading to a proinflammatory phenotype within the liver and release of TNFα into the systemic circulation causing the consequent endothelial dysfunction and cardiac phenotype that we observed.</p><p id="P56">We also demonstrated an increased albumin-bilirubin (ALBI) score, indicative of liver dysfunction. Impaired liver function affects the synthesis and metabolism of vasoactive substances, disrupts bile acid regulation, and contributes to the dysregulation of systemic hemodynamics. An increased ALBI score is associated with increased mortality risk in heart failure patients<sup><xref ref-type="bibr" rid="R58">58</xref></sup>. Whilst HXOR KO mice did not express increased levels of traditional markers of hepatocyte damage (ALT, AST, and ALP) this could be attributed to the collection of plasma used for the biochemical analysis interfering with the sensitivity of the assays<sup><xref ref-type="bibr" rid="R59">59</xref></sup>. However, ALBI score has demonstrated an ability to show earlier indications of liver disease than the traditional prognostic biomarkers<sup><xref ref-type="bibr" rid="R60">60</xref></sup>. These observations do highlight, however, the impact of liver health upon cardiac and vascular function.</p><p id="P57">We sought to investigate a physiological role for XOR mediated bioconversion of nitrite to NO in the setting of leukocyte recruitment, since a key property of endothelium-derived NO is its anti-inflammatory effect<sup><xref ref-type="bibr" rid="R61">61</xref></sup>. Under basal conditions leukocyte rolling and adhesion were elevated in <italic>Xdh<sup>+/-</sup></italic> mice compared to <italic>Xdh<sup>+/+</sup>,</italic> with the same magnitude of response observed in HXOR KO mice vs <italic>Xdh<sup>fl/fl</sup>.</italic> This is in contrast to a study in cats treated with allopurinol (under basal conditions) where no change in leukocyte adhesion or emigration was evidenced compared to control<sup><xref ref-type="bibr" rid="R62">62</xref></sup>. This discrepancy can likely be explained by the fact that in this study cats were administered heparin before assessment. Heparin will compete with endothelial GAGs, to which circulating XOR binds, and thus reduce surface endothelium XOR expression and therefore impacting leukocyte binding<sup><xref ref-type="bibr" rid="R63">63</xref></sup>. We suggest that there is a dual action of endothelial GAG-bound XOR: purine degradation resulting in superoxide and hydrogen peroxide production both of which elicit leukocyte recruitment<sup><xref ref-type="bibr" rid="R62">62</xref></sup>, and nitrite reduction to NO which inhibits leukocyte recruitment<sup><xref ref-type="bibr" rid="R64">64</xref>,<xref ref-type="bibr" rid="R65">65</xref></sup>. Our observation suggests that under basal conditions, the reduction in NO production has a more prominent effect on leukocyte recruitment than the reduction in ROS generation.</p><p id="P58">It is well accepted that NO reduces leukocyte endothelium interactions and hence recruitment. The mechanisms by which it does this include suppression of CD62P, CD62E and VCAM-1 expression on endothelial cells<sup><xref ref-type="bibr" rid="R66">66</xref>,<xref ref-type="bibr" rid="R67">67</xref></sup>. Indeed, in <italic>Xdh<sup>+/-</sup></italic> and HXOR KO mice we observed an increase in endothelial CD62P expression within the liver, which likely accounts for the observed elevated leukocyte rolling, in line with previous data demonstrating that NO regulates endothelial CD62P expression<sup><xref ref-type="bibr" rid="R68">68</xref></sup>. These results suggest that under basal conditions, hepatic XOR likely binding to endothelium via interaction with GAGs leads to XOR-dependent nitrite derived NO that plays a role in sustaining a quiescent endothelium. Since XOR is implicated in I/R injury (for review see<sup><xref ref-type="bibr" rid="R69">69</xref></sup>) an effect attributed to XOR-derived ROS<sup><xref ref-type="bibr" rid="R62">62</xref></sup>, and oxidative stress-induced expression of TNFα and MCP-1<sup><xref ref-type="bibr" rid="R70">70</xref></sup> we assessed the impact of XOR deletion in a mesenteric artery I/R injury model. We observed an increase in leukocyte recruitment in <italic>Xdh<sup>+/+</sup></italic> mice subjected to I/R injury, with no change in <italic>Xdh<sup>+/-</sup></italic> mice; an effect concordant with observations by others assessing the impact of renal I/R injury in a similar mouse<sup><xref ref-type="bibr" rid="R70">70</xref></sup>. Collectively our observations confirm that reducing XOR-derived ROS in the setting of I/R injury is beneficial. But that under physiological conditions XOR-derived NO is important for maintaining vessel homeostasis to limit leukocyte recruitment and vascular dysfunction. There are limited studies investigating XOR expression on leukocytes however we did identify XOR expression in neutrophils (others have suggested XOR expression in macrophages predominantly<sup><xref ref-type="bibr" rid="R71">71</xref>,<xref ref-type="bibr" rid="R72">72</xref></sup>). However, we saw no change in activation state of any leukocyte subtype assessed, supporting our contention that the anti-leukocyte effects observed likely relate to endothelium-bound XOR.</p><p id="P59">A complication of XOR inhibition <italic>in vivo</italic> is that using allopurinol/febuxostat or genetic deletion, will inhibit UA, ROS and NO production making identification of which pathways are the key drivers for any phenotype seen complex. An alternative method for targeting XOR is by providing an excess of substrate that would drive one of the synthesis pathways. Indeed, to assess XOR-dependent nitrite reduction comparison of the effects of elevating circulating nitrite as a substrate provides such an approach. In our study, dietary inorganic nitrate treatment elevated circulating nitrite in wild types and XOR-deleted mice. This rise in nitrite was associated with a reduction in leukocyte rolling in <italic>Xdh<sup>+/+</sup></italic> mice subjected to I/R injury, whilst there was no effect in <italic>Xdh<sup>+/-</sup></italic>, confirming XOR as a nitrite reductase and demonstrating a functional effect <italic>in vivo</italic>.</p><p id="P60">In summary, we have demonstrated a critical role for the nitrite reductase activity of hepatic XOR <italic>in vivo</italic>. Our data support the hypothesis that in physiological conditions hepatic XOR functions as a nitrite reductase to sustain cardiovascular health. Additionally, in diseases such as hypertension, heart failure or coronary artery disease, conditions associated with reductions in circulating nitrite and nitrate, that correcting circulating nitrite levels using inorganic nitrate to enhance XOR activity, and thus NO generation, might be a preferable therapeutic strategy (as shown recently<sup><xref ref-type="bibr" rid="R73">73</xref>,<xref ref-type="bibr" rid="R74">74</xref></sup>) rather than inhibition of the enzyme to reduce UA or ROS. We suggest that these findings highlight the potential for exploitation of XOR as a nitrite reductase, through nitrate/nitrite delivery, in sustaining cardiovascular health and in treating disease where XOR expression is elevated.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplemental Methods and Results</label><media xlink:href="EMS199926-supplement-Supplemental_Methods_and_Results.docx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" id="d107aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S34"><title>Acknowledgements</title><p>We would like to extend our sincere thanks to the Cortese-Krott lab for their invaluable assistance in establishing their refined FMD protocol, which was instrumental in our study. Their expertise and support significantly contributed to the success of our research.</p><sec id="S35"><title>Sources of Funding</title><p>Nicki Dyson (FS/19/62/34901) and Lorna Gee (FS/13/58/30648) were funded by BHF MRes/PhD Studentships. The development of the hepatic mouse model was funded by The Barts Charity Seed Grant (MGU0380). Tipparat Parakaw was funded by an EU ITN (675111). Krishnaraj Rathod was funded by the National Institute for Health and Care Research (NIHR) (DRF-2014-07-008) and NIHR ACL. Gianmichele Massimo was funded by The Barts Charity Cardiovascular Programme MRG00913. Claudia P Cabrera acknowledges the support of the National Institute for Health and Care Research Barts Biomedical Research Centre.</p></sec></ack><sec id="S36" sec-type="data-availability"><title>Data Availability</title><p id="P61">The data that support the findings of this study are available on reasonable request from the corresponding author, [AA].</p></sec><fn-group><fn id="FN1" fn-type="conflict"><p id="P62"><bold>Disclosures</bold></p><p id="P63">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:</p><p id="P64">Amrita Ahluwalia is a Co-Director of Heartbeet Ltd and IoNa Therapeutics seeking to identify therapeutic opportunities for dietary nitrate.</p></fn><fn id="FN2"><p id="P65"><bold>CreDit Nomenclature</bold></p><p id="P66">ND: data collection, data curation, formal analysis, data interpretation, writing – original draft and takes responsibility for the data.</p><p id="P67">RSK: data collection, data curation, formal analysis, data interpretation, writing – original draft</p><p id="P68">TP: data collection, reviewing– original draft</p><p id="P69">GM: data collection, reviewing–original draft</p><p id="P70">NHHK: data collection, reviewing–original draft</p><p id="P71">AAN: data collection, reviewing–original draft</p><p id="P72">LCG: data collection, reviewing–original draft</p><p id="P73">IL: data collection, reviewing–original draft</p><p id="P74">US: data collection, reviewing–original draft</p><p id="P75">AJS: data collection, reviewing–original draft</p><p id="P76">JWH: data collection, reviewing–original draft</p><p id="P77">KSR: data collection, reviewing–original draft</p><p id="P78">MRB: formal analysis, reviewing–original draft</p><p id="P79">CPC: formal analysis, reviewing–original draft</p><p id="P80">AA: conceptualisation, funding acquisition, investigation, methodology, data interpretation, writing – original draft and takes responsibility for the data.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linder</surname><given-names>N</given-names></name><name><surname>Rapola</surname><given-names>J</given-names></name><name><surname>Raivio</surname><given-names>KO</given-names></name></person-group><article-title>Cellular expression of xanthine oxidoreductase protein in normal human tissues</article-title><source>LAB INVEST</source><year>1999</year><volume>79</volume><fpage>967</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">10462034</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarasch</surname><given-names>ED</given-names></name><name><surname>Bruder</surname><given-names>G</given-names></name><name><surname>Heid</surname><given-names>HW</given-names></name></person-group><article-title>Significance of xanthine oxidase in capillary endothelial cells</article-title><source>Acta Physiol Scand Suppl</source><year>1986</year><volume>548</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">3463124</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarasch</surname><given-names>ED</given-names></name><name><surname>Grund</surname><given-names>C</given-names></name><name><surname>Bruder</surname><given-names>G</given-names></name><name><surname>Heid</surname><given-names>HW</given-names></name><name><surname>Keenan</surname><given-names>TW</given-names></name><name><surname>Franke</surname><given-names>WW</given-names></name></person-group><article-title>Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium</article-title><source>Cell</source><year>1981</year><volume>25</volume><fpage>67</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">6895049</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouquette</surname><given-names>M</given-names></name><name><surname>Page</surname><given-names>S</given-names></name><name><surname>Bryant</surname><given-names>R</given-names></name><name><surname>Benboubetra</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>CR</given-names></name><name><surname>Blake</surname><given-names>DR</given-names></name><name><surname>Whish</surname><given-names>WD</given-names></name><name><surname>Harrison</surname><given-names>R</given-names></name><name><surname>Tosh</surname><given-names>D</given-names></name></person-group><article-title>Xanthine oxidoreductase is asymmetrically localised on the outer surface of human endothelial and epithelial cells in culture</article-title><source>FEBS Lett</source><year>1998</year><volume>426</volume><fpage>397</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">9600274</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>AJ</given-names></name><name><surname>Milsom</surname><given-names>AB</given-names></name><name><surname>Rathod</surname><given-names>KS</given-names></name><name><surname>Chu</surname><given-names>WL</given-names></name><name><surname>Qureshi</surname><given-names>S</given-names></name><name><surname>Lovell</surname><given-names>MJ</given-names></name><name><surname>Lecomte</surname><given-names>FM</given-names></name><name><surname>Perrett</surname><given-names>D</given-names></name><name><surname>Raimondo</surname><given-names>C</given-names></name><name><surname>Khoshbin</surname><given-names>E</given-names></name><etal/></person-group><article-title>Mechanisms underlying erythrocyte and endothelial nitrite reduction to nitric oxide in hypoxia: role for xanthine oxidoreductase and endothelial nitric oxide synthase</article-title><source>Circulation Research</source><year>2008</year><volume>103</volume><fpage>957</fpage><lpage>964</lpage><pub-id pub-id-type="pmcid">PMC2841343</pub-id><pub-id pub-id-type="pmid">18818408</pub-id><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.175810</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>Spiekermann</surname><given-names>S</given-names></name><name><surname>Preuss</surname><given-names>C</given-names></name><name><surname>Sorrentino</surname><given-names>S</given-names></name><name><surname>Fischer</surname><given-names>D</given-names></name><name><surname>Manes</surname><given-names>C</given-names></name><name><surname>Mueller</surname><given-names>M</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name></person-group><article-title>Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease</article-title><source>Artehoscler Thromb Vasc Biol</source><year>2007</year><volume>27</volume><fpage>943</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">17234726</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzik</surname><given-names>TJ</given-names></name><name><surname>Sadowski</surname><given-names>J</given-names></name><name><surname>Guzik</surname><given-names>B</given-names></name><name><surname>Jopek</surname><given-names>A</given-names></name><name><surname>Kapelak</surname><given-names>B</given-names></name><name><surname>Przybylowski</surname><given-names>P</given-names></name><name><surname>Wierzbicki</surname><given-names>K</given-names></name><name><surname>Korbut</surname><given-names>R</given-names></name><name><surname>Harrison</surname><given-names>DG</given-names></name><name><surname>Channon</surname><given-names>KM</given-names></name></person-group><article-title>Coronary Artery Superoxide Production and Nox Isoform Expression in Human Coronary Artery Disease</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><year>2006</year><volume>26</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">16293794</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiekermann</surname><given-names>S</given-names></name><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>Dikalov</surname><given-names>S</given-names></name><name><surname>Bredt</surname><given-names>M</given-names></name><name><surname>Gamez</surname><given-names>G</given-names></name><name><surname>Tatge</surname><given-names>H</given-names></name><name><surname>Reepschläger</surname><given-names>N</given-names></name><name><surname>Hornig</surname><given-names>B</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name><name><surname>Harrison</surname><given-names>DG</given-names></name></person-group><article-title>Electron Spin Resonance Characterization of Vascular Xanthine and NAD(P)H Oxidase Activity in Patients With Coronary Artery Disease: Relation to Endothelium-Dependent Vasodilation</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>1383</fpage><lpage>1389</lpage><pub-id pub-id-type="pmid">12642358</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granger</surname><given-names>DN</given-names></name><name><surname>Benoit</surname><given-names>JN</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Grisham</surname><given-names>MB</given-names></name></person-group><article-title>Leukocyte adherence to venular endothelium during ischemia-reperfusion</article-title><source>American Journal of Physiology-Gastrointestinal and Liver Physiology</source><year>1989</year><volume>257</volume><fpage>G683</fpage><lpage>G688</lpage><pub-id pub-id-type="pmid">2596604</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>MA</given-names></name><name><surname>Sanchez-Lozada</surname><given-names>LG</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name><name><surname>Kang</surname><given-names>DH</given-names></name></person-group><article-title>Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction</article-title><source>J Hypertens</source><year>2010</year><volume>28</volume><fpage>1234</fpage><lpage>1242</lpage><pub-id pub-id-type="pmid">20486275</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>N</given-names></name></person-group><article-title>Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: A mechanism for uric acid-induced endothelial dysfunction</article-title><source>Int J Mol Med</source><year>2016</year><pub-id pub-id-type="pmcid">PMC4790645</pub-id><pub-id pub-id-type="pmid">26935704</pub-id><pub-id pub-id-type="doi">10.3892/ijmm.2016.2491</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>GN</given-names></name><name><surname>Frei</surname><given-names>B</given-names></name><name><surname>Koulouris</surname><given-names>SN</given-names></name><name><surname>Gerhard</surname><given-names>MD</given-names></name><name><surname>Keaney</surname><given-names>JF</given-names></name><name><surname>Vita</surname><given-names>JA</given-names></name></person-group><article-title>Ascorbic Acid Reverses Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease</article-title><source>Circulation</source><year>1996</year><volume>93</volume><fpage>1107</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">8653830</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keaney</surname><given-names>JF</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Jackson</surname><given-names>T</given-names></name><name><surname>Frei</surname><given-names>B</given-names></name><name><surname>Vita</surname><given-names>JA</given-names></name></person-group><article-title>Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation</article-title><source>J Clin Invest</source><year>1995</year><volume>95</volume><fpage>2520</fpage><lpage>2529</lpage><pub-id pub-id-type="pmcid">PMC295934</pub-id><pub-id pub-id-type="pmid">7769097</pub-id><pub-id pub-id-type="doi">10.1172/JCI117953</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Samouilov</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zweier</surname><given-names>JL</given-names></name></person-group><article-title>Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrite reduction. Evaluation of its role in nitric oxide generation in anoxic tissues</article-title><source>Journal of Biological Chemistry</source><year>2001</year><volume>276</volume><fpage>24482</fpage><lpage>24489</lpage><pub-id pub-id-type="pmid">11312267</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godber</surname><given-names>BL</given-names></name><name><surname>Doel</surname><given-names>JJ</given-names></name><name><surname>Sapkota</surname><given-names>GP</given-names></name><name><surname>Blake</surname><given-names>DR</given-names></name><name><surname>Stevens</surname><given-names>CR</given-names></name><name><surname>Eisenthal</surname><given-names>R</given-names></name><name><surname>Harrison</surname><given-names>R</given-names></name></person-group><article-title>Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase</article-title><source>J BiolChem</source><year>2000</year><volume>275</volume><fpage>7757</fpage><lpage>7763</lpage><pub-id pub-id-type="pmid">10713088</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname></name><name><surname>Naughton</surname><given-names>D</given-names></name><name><surname>Winyard</surname><given-names>PG</given-names></name><name><surname>Benjamin</surname><given-names>N</given-names></name><name><surname>Blake</surname><given-names>DR</given-names></name><name><surname>Symons</surname><given-names>MC</given-names></name></person-group><article-title>Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity</article-title><source>Biochem Biophys Res Commun</source><year>1998</year><volume>249</volume><fpage>767</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">9731211</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millar</surname><given-names>TM</given-names></name><name><surname>Stevens</surname><given-names>CR</given-names></name><name><surname>Benjamin</surname><given-names>N</given-names></name><name><surname>Eisenthal</surname><given-names>R</given-names></name><name><surname>Harrison</surname><given-names>R</given-names></name><name><surname>Blake</surname><given-names>DR</given-names></name></person-group><article-title>Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions</article-title><source>FEBS Lett</source><year>1998</year><volume>427</volume><fpage>225</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">9607316</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khambata</surname><given-names>RS</given-names></name><name><surname>Ghosh</surname><given-names>SM</given-names></name><name><surname>Ahluwalia</surname><given-names>A</given-names></name></person-group><article-title>“Repurposing” of Xanthine Oxidoreductase as a Nitrite Reductase: A New Paradigm for Therapeutic Targeting in Hypertension</article-title><source>Antioxidants &amp; Redox Signaling</source><year>2015</year><volume>23</volume><fpage>340</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">25714611</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapil</surname><given-names>V</given-names></name><name><surname>Khambata</surname><given-names>RS</given-names></name><name><surname>Jones</surname><given-names>DA</given-names></name><name><surname>Rathod</surname><given-names>K</given-names></name><name><surname>Primus</surname><given-names>C</given-names></name><name><surname>Massimo</surname><given-names>G</given-names></name><name><surname>Fukuto</surname><given-names>JM</given-names></name><name><surname>Ahluwalia</surname><given-names>A</given-names></name></person-group><article-title>The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway</article-title><source>Pharmacol Rev</source><year>2020</year><volume>72</volume><fpage>692</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">32576603</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>C</given-names></name><name><surname>Dougall</surname><given-names>H</given-names></name><name><surname>Johnston</surname><given-names>P</given-names></name><name><surname>Green</surname><given-names>S</given-names></name><name><surname>Brogan</surname><given-names>R</given-names></name><name><surname>Leifert</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Golden</surname><given-names>M</given-names></name><name><surname>Benjamin</surname><given-names>NCINNMJ</given-names></name></person-group><article-title>Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate</article-title><source>Nature medicine</source><year>1995</year><volume>1</volume><fpage>546</fpage><lpage>551</lpage><comment>Pmid</comment><pub-id pub-id-type="pmid">7585121</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundberg</surname><given-names>JO</given-names></name><name><surname>Weitzberg</surname><given-names>E</given-names></name><name><surname>Lundberg</surname><given-names>JM</given-names></name><name><surname>Alving</surname><given-names>K</given-names></name></person-group><article-title>Intragastric nitric oxide production in humans: measurements in expelled air</article-title><source>Gut</source><year>1994</year><volume>35</volume><fpage>1543</fpage><lpage>1546</lpage><pub-id pub-id-type="pmcid">PMC1375608</pub-id><pub-id pub-id-type="pmid">7828969</pub-id><pub-id pub-id-type="doi">10.1136/gut.35.11.1543</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>AJ</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Loukogeorgakis</surname><given-names>S</given-names></name><name><surname>Okorie</surname><given-names>M</given-names></name><name><surname>Aboud</surname><given-names>Z</given-names></name><name><surname>Misra</surname><given-names>S</given-names></name><name><surname>Rashid</surname><given-names>R</given-names></name><name><surname>Miall</surname><given-names>P</given-names></name><name><surname>Deanfield</surname><given-names>J</given-names></name><name><surname>Benjamin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite</article-title><source>Hypertension</source><year>2008</year><volume>51</volume><fpage>784</fpage><lpage>790</lpage><pub-id pub-id-type="pmcid">PMC2839282</pub-id><pub-id pub-id-type="pmid">18250365</pub-id><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.107.103523</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>SM</given-names></name><name><surname>Kapil</surname><given-names>V</given-names></name><name><surname>Fuentes-Calvo</surname><given-names>I</given-names></name><name><surname>Bubb</surname><given-names>KJ</given-names></name><name><surname>Pearl</surname><given-names>V</given-names></name><name><surname>Milsom</surname><given-names>AB</given-names></name><name><surname>Khambata</surname><given-names>R</given-names></name><name><surname>Maleki-Toyserkani</surname><given-names>S</given-names></name><name><surname>Yousuf</surname><given-names>M</given-names></name><name><surname>Benjamin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Enhanced Vasodilator Activity of Nitrite in Hypertension: Critical Role for Erythrocytic Xanthine Oxidoreductase and Translational Potential</article-title><source>Hypertension</source><year>2013</year><volume>61</volume><fpage>1091</fpage><lpage>1102</lpage><pub-id pub-id-type="pmid">23589565</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtsubo</surname><given-names>T</given-names></name><name><surname>Rovira</surname><given-names>II</given-names></name><name><surname>Starost</surname><given-names>MF</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Finkel</surname><given-names>T</given-names></name></person-group><article-title>Xanthine Oxidoreductase Is an Endogenous Regulator of Cyclooxygenase-2</article-title><source>Circulation Research</source><year>2004</year><volume>95</volume><fpage>1118</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">15528468</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khambata</surname><given-names>RS</given-names></name><name><surname>Ghosh</surname><given-names>SM</given-names></name><name><surname>Rathod</surname><given-names>KS</given-names></name><name><surname>Thevathasan</surname><given-names>T</given-names></name><name><surname>Filomena</surname><given-names>F</given-names></name><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Ahluwalia</surname><given-names>A</given-names></name></person-group><article-title>Antiinflammatory actions of inorganic nitrate stabilize the atherosclerotic plaque</article-title><source>Proc Natl Acad Sci U S A</source><year>2017</year><volume>114</volume><fpage>E550</fpage><lpage>E559</lpage><pub-id pub-id-type="pmcid">PMC5278489</pub-id><pub-id pub-id-type="pmid">28057862</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1613063114</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gee</surname><given-names>LC</given-names></name><name><surname>Massimo</surname><given-names>G</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Primus</surname><given-names>C</given-names></name><name><surname>Fernandes</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Rathod</surname><given-names>KS</given-names></name><name><surname>Hamers</surname><given-names>AJP</given-names></name><name><surname>Filomena</surname><given-names>F</given-names></name><name><surname>Nuredini</surname><given-names>G</given-names></name><etal/></person-group><article-title>Inorganic nitrate attenuates cardiac dysfunction: roles for xanthine oxidoreductase and nitric oxide</article-title><source>British Journal of Pharmacology</source><year>2022</year><volume>179</volume><fpage>4757</fpage><lpage>4777</lpage><pub-id pub-id-type="pmid">34309015</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leo</surname><given-names>F</given-names></name><name><surname>Suvorava</surname><given-names>T</given-names></name><name><surname>Heuser</surname><given-names>SK</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>LoBue</surname><given-names>A</given-names></name><name><surname>Barbarino</surname><given-names>F</given-names></name><name><surname>Piragine</surname><given-names>EA-O</given-names></name><name><surname>Schneckmann</surname><given-names>RA-OX</given-names></name><name><surname>Hutzler</surname><given-names>B</given-names></name><name><surname>Good</surname><given-names>MA-O</given-names></name><etal/></person-group><article-title>Red Blood Cell and Endothelial eNOS Independently Regulate Circulating Nitric Oxide Metabolites and Blood Pressure</article-title><source>Circulation</source><year>2021</year><volume>144</volume><fpage>870</fpage><lpage>889</lpage><pub-id pub-id-type="pmcid">PMC8529898</pub-id><pub-id pub-id-type="pmid">34229449</pub-id><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.049606</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>A</given-names></name><name><surname>Bond</surname><given-names>R</given-names></name><name><surname>McLean</surname><given-names>P</given-names></name><name><surname>Uppal</surname><given-names>R</given-names></name><name><surname>Benjamin</surname><given-names>N</given-names></name><name><surname>Ahluwalia</surname><given-names>A</given-names></name></person-group><article-title>Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage</article-title><source>Proceedings of The National Acadademy of Science USA</source><year>2004</year><volume>101</volume><fpage>13683</fpage><lpage>13688</lpage><pub-id pub-id-type="pmcid">PMC518813</pub-id><pub-id pub-id-type="pmid">15347817</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0402927101</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckman</surname><given-names>JS</given-names></name><name><surname>Parks</surname><given-names>DA</given-names></name><name><surname>Pearson</surname><given-names>JD</given-names></name><name><surname>Marshall</surname><given-names>PA</given-names></name><name><surname>Freeman</surname><given-names>BA</given-names></name></person-group><article-title>A sensitive fluorometric assay for measuring xanthine dehydrogenase and oxidase in tissues</article-title><source>Free RadicBiolMed</source><year>1989</year><volume>6</volume><fpage>607</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">2753392</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>N</given-names></name><name><surname>Ohtsubo</surname><given-names>T</given-names></name><name><surname>Kansui</surname><given-names>Y</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name><name><surname>Noguchi</surname><given-names>H</given-names></name><name><surname>Haga</surname><given-names>Y</given-names></name><name><surname>Nakabeppu</surname><given-names>Y</given-names></name><name><surname>Matsumura</surname><given-names>K</given-names></name><name><surname>Kitazono</surname><given-names>T</given-names></name></person-group><article-title>Mice Heterozygous for the Xanthine Oxidoreductase Gene Facilitate Lipid Accumulation in Adipocytes</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><year>2014</year><volume>34</volume><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">24158515</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Shirakabe</surname><given-names>A</given-names></name><name><surname>Okazaki</surname><given-names>H</given-names></name><name><surname>Shibata</surname><given-names>Y</given-names></name><name><surname>Goda</surname><given-names>H</given-names></name><name><surname>Shigihara</surname><given-names>S</given-names></name><name><surname>Asano</surname><given-names>K</given-names></name><name><surname>Tani</surname><given-names>K</given-names></name><name><surname>Kiuchi</surname><given-names>K</given-names></name><name><surname>Murase</surname><given-names>T</given-names></name><etal/></person-group><article-title>Plasma Xanthine Oxidoreductase (XOR) Activity in Cardiovascular Disease Outpatients</article-title><pub-id pub-id-type="pmcid">PMC7929762</pub-id><pub-id pub-id-type="pmid">33693215</pub-id><pub-id pub-id-type="doi">10.1253/circrep.CR-19-0116</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granger</surname><given-names>DN</given-names></name><name><surname>Hollwarth</surname><given-names>ME</given-names></name><name><surname>Parks</surname><given-names>DA</given-names></name></person-group><article-title>Ischemia-reperfusion injury: role of oxygen-derived free radicals</article-title><source>Acta Physiol ScandSuppl</source><year>1986</year><volume>548</volume><fpage>47</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">3529822</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>CE</given-names></name><name><surname>Hare</surname><given-names>JM</given-names></name></person-group><article-title>Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications</article-title><source>J Physiol</source><year>2004</year><volume>555</volume><fpage>589</fpage><lpage>606</lpage><pub-id pub-id-type="pmcid">PMC1664875</pub-id><pub-id pub-id-type="pmid">14694147</pub-id><pub-id pub-id-type="doi">10.1113/jphysiol.2003.055913</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>Y</given-names></name><name><surname>Beckman</surname><given-names>JS</given-names></name><name><surname>Beckman</surname><given-names>TK</given-names></name><name><surname>Wheat</surname><given-names>JK</given-names></name><name><surname>Cash</surname><given-names>TG</given-names></name><name><surname>Freeman</surname><given-names>BA</given-names></name><name><surname>Parks</surname><given-names>DA</given-names></name></person-group><article-title>Circulating xanthine oxidase: potential mediator of ischemic injury</article-title><source>Am J Physiol</source><year>1990</year><volume>258</volume><fpage>G564</fpage><lpage>G570</lpage><pub-id pub-id-type="pmid">2333969</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>EE</given-names></name></person-group><article-title>A new paradigm for XOR-catalyzed reactive species generation in the S endothelium</article-title><source>Pharmacol Rep</source><volume>67</volume><fpage>669</fpage><lpage>674</lpage><pub-id pub-id-type="pmcid">PMC4555844</pub-id><pub-id pub-id-type="pmid">26321266</pub-id><pub-id pub-id-type="doi">10.1016/j.pharep.2015.05.004</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtsubo</surname><given-names>T</given-names></name><name><surname>Matsumura</surname><given-names>K</given-names></name><name><surname>Sakagami</surname><given-names>K</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Tsuruya</surname><given-names>K</given-names></name><name><surname>Noguchi</surname><given-names>H</given-names></name><name><surname>Rovira</surname><given-names>II</given-names></name><name><surname>Finkel</surname><given-names>T</given-names></name><name><surname>Iida</surname><given-names>M</given-names></name></person-group><article-title>Xanthine Oxidoreductase Depletion Induces Renal Interstitial Fibrosis Through Aberrant Lipid and Purine Accumulation in Renal Tubules</article-title><source>Hypertension</source><year>2009</year><volume>54</volume><fpage>868</fpage><lpage>876</lpage><pub-id pub-id-type="pmcid">PMC3773720</pub-id><pub-id pub-id-type="pmid">19667249</pub-id><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.109.135152</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiekermann</surname><given-names>S</given-names></name><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>Dikalov</surname><given-names>S</given-names></name><name><surname>Bredt</surname><given-names>M</given-names></name><name><surname>Gamez</surname><given-names>G</given-names></name><name><surname>Tatge</surname><given-names>H</given-names></name><name><surname>Reepschlager</surname><given-names>N</given-names></name><name><surname>Hornig</surname><given-names>B</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name><name><surname>Harrison</surname><given-names>DG</given-names></name></person-group><article-title>Electron Spin Resonance Characterization of Vascular Xanthine and NAD(P)H Oxidase Activity in Patients With Coronary Artery Disease: Relation to Endothelium-Dependent Vasodilation</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>1383</fpage><lpage>1389</lpage></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmon</surname><given-names>DB</given-names></name><name><surname>Mandler</surname><given-names>WK</given-names></name><name><surname>Sipula</surname><given-names>IJ</given-names></name><name><surname>Dedousis</surname><given-names>N</given-names></name><name><surname>Lewis</surname><given-names>SE</given-names></name><name><surname>Eckels</surname><given-names>JT</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huckestein</surname><given-names>BR</given-names></name><name><surname>Pagano</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Hepatocyte-Specific Ablation or Whole-Body Inhibition of Xanthine Oxidoreductase in Mice Corrects Obesity-Induced Systemic Hyperuricemia Without Improving Metabolic Abnormalities</article-title><source>Diabetes</source><year>2019</year><volume>68</volume><fpage>1221</fpage><lpage>1229</lpage><pub-id pub-id-type="pmcid">PMC6610025</pub-id><pub-id pub-id-type="pmid">30936145</pub-id><pub-id pub-id-type="doi">10.2337/db18-1198</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>T</given-names></name><name><surname>Fukushima</surname><given-names>T</given-names></name><name><surname>Usami</surname><given-names>Y</given-names></name><name><surname>Hirano</surname><given-names>K</given-names></name></person-group><article-title>Binding of human xanthine oxidase to sulphated <sup><italic>7</italic></sup> glycosaminoglycans on the endothelial-cell surface</article-title><source>Biochem J</source><year>1993</year><volume>289</volume><issue>Pt 2</issue><fpage>523</fpage><lpage>527</lpage><pub-id pub-id-type="pmcid">PMC1132198</pub-id><pub-id pub-id-type="pmid">8424793</pub-id><pub-id pub-id-type="doi">10.1042/bj2890523</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>KJ</given-names></name><name><surname>Tzameli</surname><given-names>I</given-names></name><name><surname>Pissios</surname><given-names>P</given-names></name><name><surname>Rovira</surname><given-names>I</given-names></name><name><surname>Gavrilova</surname><given-names>O</given-names></name><name><surname>Ohtsubo</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Finkel</surname><given-names>T</given-names></name><name><surname>Flier</surname><given-names>JS</given-names></name><name><surname>Friedman</surname><given-names>JM</given-names></name></person-group><article-title>Xanthine Oxidoreductase Is a Regulator of Adipogenesis and PPARγ Activity</article-title><source>Cell Metab</source><year>2007</year><volume>5</volume><fpage>115</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">17276354</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignarro</surname><given-names>LJ</given-names></name><name><surname>Fukuto</surname><given-names>JM</given-names></name><name><surname>Griscavage</surname><given-names>JM</given-names></name><name><surname>Rogers</surname><given-names>NE</given-names></name><name><surname>Byrns</surname><given-names>RE</given-names></name></person-group><article-title>Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from L-arginine</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>8103</fpage><lpage>8107</lpage><pub-id pub-id-type="pmcid">PMC47296</pub-id><pub-id pub-id-type="pmid">7690141</pub-id><pub-id pub-id-type="doi">10.1073/pnas.90.17.8103</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fukuto</surname><given-names>JM</given-names></name><name><surname>Cho</surname><given-names>JY</given-names></name><name><surname>Switzer</surname><given-names>CH</given-names></name></person-group><chapter-title>The chemical proerties of nitric oxide and related nitrogen oxides</chapter-title><person-group person-group-type="editor"><name><surname>Ignarro</surname><given-names>LJ</given-names></name></person-group><source>Nitric oxide: biology and pathobiology</source><publisher-name>Academic Press</publisher-name><publisher-loc>San Diego</publisher-loc><year>2000</year><fpage>23</fpage><lpage>40</lpage></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bortolotti</surname><given-names>M</given-names></name><name><surname>Polito</surname><given-names>L</given-names></name><name><surname>Battelli</surname><given-names>MG</given-names></name><name><surname>Bolognesi</surname><given-names>A</given-names></name></person-group><article-title>Xanthine oxidoreductase: One enzyme for multiple physiological tasks</article-title><source>Redox Biology</source><year>2021</year><volume>41</volume><elocation-id>101882</elocation-id><pub-id pub-id-type="pmcid">PMC7879036</pub-id><pub-id pub-id-type="pmid">33578127</pub-id><pub-id pub-id-type="doi">10.1016/j.redox.2021.101882</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>XM</given-names></name><name><surname>Bossert</surname><given-names>AT</given-names></name><name><surname>Devalance</surname><given-names>E</given-names></name><name><surname>Lewis</surname><given-names>SE</given-names></name><name><surname>Gunther</surname><given-names>MR</given-names></name><name><surname>Kelley</surname><given-names>EE</given-names></name></person-group><article-title>Indirect Antioxidant Effects of the Nitrite Anion: Focus on Xanthine Oxidase</article-title><source>Adv Redox Res</source><year>2023</year><volume>7</volume><pub-id pub-id-type="pmcid">PMC10100591</pub-id><pub-id pub-id-type="pmid">37063462</pub-id><pub-id pub-id-type="doi">10.1016/j.arres.2022.100058</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erkens</surname><given-names>R</given-names></name><name><surname>Kramer</surname><given-names>CM</given-names></name><name><surname>Lückstädt</surname><given-names>W</given-names></name><name><surname>Panknin</surname><given-names>C</given-names></name><name><surname>Krause</surname><given-names>L</given-names></name><name><surname>Weidenbach</surname><given-names>M</given-names></name><name><surname>Dirzka</surname><given-names>J</given-names></name><name><surname>Krenz</surname><given-names>T</given-names></name><name><surname>Mergia</surname><given-names>E</given-names></name><name><surname>Suvorava</surname><given-names>T</given-names></name><etal/></person-group><article-title>Left ventricular diastolic dysfunction in Nrf2 knock out mice is associated with cardiac hypertrophy, decreased expression of SERCA2a, and preserved endothelial function</article-title><source>Free Radic Biol Med</source><year>2015</year><volume>89</volume><fpage>906</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">26475037</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>DJ</given-names></name><name><surname>Dawson</surname><given-names>EA</given-names></name><name><surname>Groenewoud</surname><given-names>HMM</given-names></name><name><surname>Jones</surname><given-names>H</given-names></name><name><surname>Thijssen</surname><given-names>DHJ</given-names></name></person-group><article-title>Is Flow-Mediated Dilation Nitric Oxide Mediated?: A Meta-Analysis</article-title><source>Hypertension</source><year>2014</year><volume>63</volume><fpage>376</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">24277765</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grayson</surname><given-names>PC</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>LaValley</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>HK</given-names></name></person-group><article-title>Hyperuricemia and incident hypertension: a systematic review and meta-analysis</article-title><source>Arthritis Care Res (Hoboken)</source><year>2011</year><volume>63</volume><fpage>102</fpage><lpage>110</lpage><pub-id pub-id-type="pmcid">PMC3016454</pub-id><pub-id pub-id-type="pmid">20824805</pub-id><pub-id pub-id-type="doi">10.1002/acr.20344</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Kurajoh</surname><given-names>M</given-names></name><name><surname>Fukumoto</surname><given-names>S</given-names></name><name><surname>Murase</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Inaba</surname><given-names>M</given-names></name><name><surname>Emoto</surname><given-names>M</given-names></name></person-group><article-title>Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><elocation-id>4437</elocation-id><pub-id pub-id-type="pmcid">PMC7064483</pub-id><pub-id pub-id-type="pmid">32157204</pub-id><pub-id pub-id-type="doi">10.1038/s41598-020-61463-8</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>V</given-names></name><name><surname>Hans</surname><given-names>N</given-names></name><name><surname>Messerli</surname><given-names>FH</given-names></name></person-group><article-title>Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta-Analysis</article-title><source>The Journal of Clinical Hypertension</source><year>2013</year><volume>15</volume><fpage>435</fpage><lpage>442</lpage><pub-id pub-id-type="pmcid">PMC8033809</pub-id><pub-id pub-id-type="pmid">23730993</pub-id><pub-id pub-id-type="doi">10.1111/j.1751-7176.2012.00701.x</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noman</surname><given-names>A</given-names></name><name><surname>Ang</surname><given-names>DS</given-names></name><name><surname>Ogston</surname><given-names>S</given-names></name><name><surname>Lang</surname><given-names>CC</given-names></name><name><surname>Struthers</surname><given-names>AD</given-names></name></person-group><article-title>Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>2161</fpage><lpage>2167</lpage><pub-id pub-id-type="pmcid">PMC2890860</pub-id><pub-id pub-id-type="pmid">20542554</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60391-1</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostka-Jeziorny</surname><given-names>K</given-names></name><name><surname>Uruski</surname><given-names>P</given-names></name><name><surname>Tykarski</surname><given-names>A</given-names></name></person-group><article-title>Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients</article-title><source>Blood Press</source><year>2011</year><volume>20</volume><fpage>104</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">21405957</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feig</surname><given-names>DI</given-names></name><name><surname>Soletsky</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name></person-group><article-title>Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial</article-title><source>JAMA</source><year>2008</year><volume>300</volume><fpage>924</fpage><lpage>932</lpage><pub-id pub-id-type="pmcid">PMC2684336</pub-id><pub-id pub-id-type="pmid">18728266</pub-id><pub-id pub-id-type="doi">10.1001/jama.300.8.924</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>YP</given-names></name><name><surname>Leung</surname><given-names>KT</given-names></name><name><surname>Tong</surname><given-names>MK</given-names></name><name><surname>Kwan</surname><given-names>TH</given-names></name></person-group><article-title>Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level</article-title><source>Am J Kidney Dis</source><year>2006</year><volume>47</volume><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">16377385</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peleli</surname><given-names>M</given-names></name><name><surname>Zollbrecht</surname><given-names>C</given-names></name><name><surname>Montenegro</surname><given-names>MF</given-names></name><name><surname>Hezel</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Persson</surname><given-names>EG</given-names></name><name><surname>Holmdahl</surname><given-names>R</given-names></name><name><surname>Weitzberg</surname><given-names>E</given-names></name><name><surname>Lundberg</surname><given-names>JO</given-names></name><name><surname>Carlstrom</surname><given-names>M</given-names></name></person-group><article-title>Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis</article-title><source>Free Radic Biol Med</source><year>2016</year><volume>99</volume><fpage>472</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">27609225</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Soud</surname><given-names>HM</given-names></name><name><surname>Ichimori</surname><given-names>K</given-names></name><name><surname>Presta</surname><given-names>A</given-names></name><name><surname>Stuehr</surname><given-names>DJ</given-names></name></person-group><article-title>Electron transfer, oxygen binding, and nitric oxide feedback inhibition in endothelial nitric-oxide synthase</article-title><source>Journal of Biological Chemistry</source><year>2000</year><volume>275</volume><fpage>17349</fpage><lpage>17357</lpage><pub-id pub-id-type="pmid">10749853</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HM</given-names></name><name><surname>Wood</surname><given-names>KC</given-names></name><name><surname>Lewis</surname><given-names>SE</given-names></name><name><surname>Hahn</surname><given-names>SA</given-names></name><name><surname>Williams</surname><given-names>XM</given-names></name><name><surname>McMahon</surname><given-names>B</given-names></name><name><surname>Baust</surname><given-names>JJ</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Bachman</surname><given-names>TN</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Xanthine Oxidase Drives Hemolysis and Vascular Malfunction in Sickle Cell Disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2021</year><volume>41</volume><fpage>769</fpage><lpage>782</lpage><pub-id pub-id-type="pmcid">PMC8185582</pub-id><pub-id pub-id-type="pmid">33267657</pub-id><pub-id pub-id-type="doi">10.1161/ATVBAHA.120.315081</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kane</surname><given-names>AE</given-names></name><name><surname>Bisset</surname><given-names>ES</given-names></name><name><surname>Heinze-Milne</surname><given-names>S</given-names></name><name><surname>Keller</surname><given-names>KM</given-names></name><name><surname>Grandy</surname><given-names>SA</given-names></name><name><surname>Howlett</surname><given-names>SE</given-names></name></person-group><article-title>Maladaptive Changes Associated With Cardiac Aging Are Sex-Specific and Graded by Frailty and Inflammation in C57BL/6 Mice</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2021</year><volume>76</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="pmcid">PMC7812442</pub-id><pub-id pub-id-type="pmid">32857156</pub-id><pub-id pub-id-type="doi">10.1093/gerona/glaa212</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Tong</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name></person-group><article-title>Prognostic impact of albumin-bilirubin score on the prediction of in-hospital mortality in patients with heart failure: a retrospective cohort study</article-title><source>BMJ Open</source><year>2022</year><volume>12</volume><elocation-id>e049325</elocation-id><pub-id pub-id-type="pmcid">PMC8728421</pub-id><pub-id pub-id-type="pmid">34983753</pub-id><pub-id pub-id-type="doi">10.1136/bmjopen-2021-049325</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohri</surname><given-names>M</given-names></name><name><surname>Rezapoor</surname><given-names>H</given-names></name></person-group><article-title>Effects of heparin, citrate, and EDTA on plasma biochemistry of sheep: comparison with serum</article-title><source>Res Vet Sci</source><year>2009</year><volume>86</volume><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">18572209</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyoda</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>PJ</given-names></name></person-group><article-title>The ALBI score: From liver function in patients with HCC to a general measure of liver function</article-title><source>JHEP Rep</source><year>2022</year><volume>4</volume><elocation-id>100557</elocation-id><pub-id pub-id-type="pmcid">PMC9482109</pub-id><pub-id pub-id-type="pmid">36124124</pub-id><pub-id pub-id-type="doi">10.1016/j.jhepr.2022.100557</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moncada</surname><given-names>S</given-names></name><name><surname>Higgs</surname><given-names>A</given-names></name></person-group><article-title>The L-Arginine-Nitric Oxide Pathway</article-title><source>New England Journal of Medicine</source><year>1993</year><volume>329</volume><fpage>2002</fpage><lpage>2012</lpage><pub-id pub-id-type="pmid">7504210</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Inauen</surname><given-names>W</given-names></name><name><surname>Kvietys</surname><given-names>PR</given-names></name><name><surname>Grisham</surname><given-names>MB</given-names></name><name><surname>Meininger</surname><given-names>C</given-names></name><name><surname>Schelling</surname><given-names>ME</given-names></name><name><surname>Granger</surname><given-names>HJ</given-names></name><name><surname>Granger</surname><given-names>DN</given-names></name></person-group><article-title>Superoxide mediates reperfusion-induced leukocyte-endothelial cell interactions</article-title><source>Am J Physiol</source><year>1989</year><volume>257</volume><fpage>H1740</fpage><lpage>1745</lpage><pub-id pub-id-type="pmid">2556051</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houston</surname><given-names>M</given-names></name><name><surname>Estevez</surname><given-names>A</given-names></name><name><surname>Chumley</surname><given-names>P</given-names></name><name><surname>Aslan</surname><given-names>M</given-names></name><name><surname>Marklund</surname><given-names>S</given-names></name><name><surname>Parks</surname><given-names>DA</given-names></name><name><surname>Freeman</surname><given-names>BA</given-names></name></person-group><article-title>Binding of Xanthine Oxidase to Vascular Endothelium: KINETIC CHARACTERIZATION AND OXIDATIVE IMPAIRMENT OF NITRIC OXIDE-DEPENDENT SIGNALING</article-title><source>Journal of Biological Chemistry</source><year>1999</year><volume>274</volume><fpage>4985</fpage><lpage>4994</lpage><pub-id pub-id-type="pmid">9988743</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubes</surname><given-names>P</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Granger</surname><given-names>DN</given-names></name></person-group><article-title>Nitric oxide: an endogenous modulator of leukocyte adhesion</article-title><source>ProcNatlAcadSciUSA</source><year>1991</year><volume>88</volume><fpage>4651</fpage><lpage>4655</lpage><pub-id pub-id-type="pmcid">PMC51723</pub-id><pub-id pub-id-type="pmid">1675786</pub-id><pub-id pub-id-type="doi">10.1073/pnas.88.11.4651</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hickey</surname><given-names>MJ</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name></person-group><article-title>Role of nitric oxide in regulation of leucocyte-endothelial cell interactions</article-title><source>ExpPhysiol</source><year>1997</year><volume>82</volume><fpage>339</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">9129948</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Peng</surname><given-names>HB</given-names></name><name><surname>Thannickal</surname><given-names>VJ</given-names></name><name><surname>Rajavashisth</surname><given-names>TB</given-names></name><name><surname>Gimbrone</surname><given-names>MA</given-names><suffix>Jr</suffix></name><name><surname>Shin</surname><given-names>WS</given-names></name><name><surname>Liao</surname><given-names>JK</given-names></name></person-group><article-title>Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines</article-title><source>The Journal of Clinical Investigation</source><year>1995</year><volume>96</volume><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="pmcid">PMC185173</pub-id><pub-id pub-id-type="pmid">7542286</pub-id><pub-id pub-id-type="doi">10.1172/JCI118074</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenpeck</surname><given-names>KL</given-names></name><name><surname>Gauthier</surname><given-names>TW</given-names></name><name><surname>Lefer</surname><given-names>AM</given-names></name></person-group><article-title>Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation</article-title><source>Gastroenterology</source><year>1994</year><volume>107</volume><fpage>1050</fpage><lpage>1058</lpage><pub-id pub-id-type="pmid">7523213</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstead</surname><given-names>VE</given-names></name><name><surname>Minchenko</surname><given-names>AG</given-names></name><name><surname>Schuhl</surname><given-names>RA</given-names></name><name><surname>Hayward</surname><given-names>R</given-names></name><name><surname>Nossuli</surname><given-names>TO</given-names></name><name><surname>Lefer</surname><given-names>AM</given-names></name></person-group><article-title>Regulation of P-selectin expression in human endothelial cells by nitric oxide</article-title><source>American Journal of Physiology-Heart and Circulatory Physiology</source><year>1997</year><volume>273</volume><fpage>H740</fpage><lpage>H746</lpage><pub-id pub-id-type="pmid">9277491</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto-Moure</surname><given-names>B</given-names></name><name><surname>Carabén-Redaño</surname><given-names>A</given-names></name><name><surname>Aliena-Valero</surname><given-names>A</given-names></name><name><surname>Cejalvo</surname><given-names>D</given-names></name><name><surname>Toledo</surname><given-names>AH</given-names></name><name><surname>Flores-Bellver</surname><given-names>M</given-names></name><name><surname>Martínez-Gil</surname><given-names>N</given-names></name><name><surname>Toledo-Pereyra</surname><given-names>LH</given-names></name><name><surname>Lloris Carsí</surname><given-names>JM</given-names></name></person-group><article-title>Allopurinol in Renal Ischemia</article-title><source>Journal of Investigative Surgery</source><year>2014</year><volume>27</volume><fpage>304</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">24914485</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haga</surname><given-names>Y</given-names></name><name><surname>Ohtsubo</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>N</given-names></name><name><surname>Noguchi</surname><given-names>H</given-names></name><name><surname>Kansui</surname><given-names>Y</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name><name><surname>Matsumura</surname><given-names>K</given-names></name><name><surname>Kitazono</surname><given-names>T</given-names></name></person-group><article-title>Disruption of xanthine oxidoreductase gene attenuates renal ischemia reperfusion injury in mice</article-title><source>Life Sciences</source><year>2017</year><volume>182</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">28625358</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellsten-Westing</surname><given-names>Y</given-names></name></person-group><article-title>Immunohistochemical localization of xanthine oxidase in human cardiac and skeletal muscle</article-title><source>Histochemistry</source><year>1993</year><volume>100</volume><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">8244772</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grum</surname><given-names>CM</given-names></name><name><surname>Gross</surname><given-names>TJ</given-names></name><name><surname>Mody</surname><given-names>CH</given-names></name><name><surname>Sitrin</surname><given-names>RG</given-names></name></person-group><article-title>Expression of xanthine oxidase activity by murine leukocytes</article-title><source>J Lab Clin Med</source><year>1990</year><volume>116</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">2118559</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>DA</given-names></name><name><surname>Beirne</surname><given-names>A-M</given-names></name><name><surname>Kelham</surname><given-names>M</given-names></name><name><surname>Wynne</surname><given-names>L</given-names></name><name><surname>Andiapen</surname><given-names>M</given-names></name><name><surname>Rathod</surname><given-names>KS</given-names></name><name><surname>Parakaw</surname><given-names>T</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Learoyd</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial</article-title><source>European Heart Journal</source><year>2024</year><volume>45</volume><fpage>1647</fpage><lpage>1658</lpage><pub-id pub-id-type="pmcid">PMC11089333</pub-id><pub-id pub-id-type="pmid">38513060</pub-id><pub-id pub-id-type="doi">10.1093/eurheartj/ehae100</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathod</surname><given-names>KS</given-names></name><name><surname>Mathur</surname><given-names>A</given-names></name><name><surname>Shabbir</surname><given-names>A</given-names></name><name><surname>Khambata</surname><given-names>RS</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Beirne</surname><given-names>A-M</given-names></name><name><surname>Chhetri</surname><given-names>I</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Belgaid</surname><given-names>DR</given-names></name><name><surname>Massimo</surname><given-names>G</given-names></name><etal/></person-group><article-title>The NITRATE-OCT study-inorganic nitrate reduces in-stent restenosis in patients with stable coronary artery disease: a double-blind, randomised controlled trial</article-title><source>eClinicalMedicine</source><year>2024</year><volume>77</volume><pub-id pub-id-type="pmcid">PMC11513660</pub-id><pub-id pub-id-type="pmid">39469537</pub-id><pub-id pub-id-type="doi">10.1016/j.eclinm.2024.102885</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Confirmation of genetic deletion of <italic>Xdh.</italic></title><p><bold>(A)</bold> Schematic of WT <italic>Xdh</italic> gene and insertion of XDH-FLOX-EM1-B6 via CRISPR/Cas9. The expression of the loxP regions in mice containing XDH-FLOX-EM1-B6 (<italic>Xdh<sup>fl/fl</sup></italic>) results in Cre mediated excision of exon 6 in mice expression Cre recombinase downstream of the albumin promoter (HXOR KO). <bold>(B)</bold> Complete <italic>Xdh</italic> open reading frame in <italic>Xdh<sup>fl/fl</sup></italic> and HXOR KO mice with 1-633 bp highlighted and integrated into remaining <italic>Xdh</italic> open reading frame protein and formation of an XOR monomer. Western blot quantification of XOR protein expression across <bold>(C)</bold> various tissues and <bold>(D)</bold> plasma in the 4-week-old global <italic>Xdh</italic> deleted mice and their wild type littermate controls. <bold>(E)</bold> XO activity as assessed by amplex red H2O2 production and <bold>(F)</bold> plasma uric acid concentration and total XOR activity (XDH and XO isoform activity) in the <bold>(G)</bold> liver and <bold>(H)</bold> plasma of samples collected from 4-week-old <italic>Xdh<sup>+/+</sup>, Xdh<sup>+/-</sup></italic> and <italic>Xdh<sup>-/-</sup></italic> mice where available. Western blot quantification of XOR protein expression across <bold>(I)</bold> various tissues, in 8-week-old and <bold>(J)</bold> plasma in the 20-week-old HXOR KO mice versus the <italic>Xdh<sup>fl/fl</sup></italic> wild type littermate controls. <bold>(K)</bold> liver homogenate XO activity assessed by amplex red H<sub>2</sub>O<sub>2</sub> production and <bold>(L)</bold> plasma uric acid concentration and total XOR activity (XDH and XO isoform activity) in the <bold>(M)</bold> liver and <bold>(N)</bold> plasma of 20-week-old <italic>Xdh fl/fl</italic> and HXOR KO littermate mice. Data are shown as mean ± SEM of n mice (shown on individual graphs). Statistical significance for genotype was determined using two-way ANOVA (shown in bottom right <bold>(C</bold>, <bold>G-I</bold>, <bold>M-N)</bold> followed by Dunnett’s <italic>post hoc</italic> test <bold>(C and I)</bold> or Sidak’s multiple <italic>post hoc</italic> test <bold>(G-H and M-N),</bold> by One-way ANOVA <bold>(D-F)</bold> followed by Dunnett’s multiple <italic>post hoc</italic> test highlighting significant difference from <italic>Xdh</italic><sup>+/+</sup> or by unpaired Student’s t-test <bold>(J-L)</bold>.</p></caption><graphic xlink:href="EMS199926-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>XOR functions as a nitrite reductase.</title><p>Levels of liver <bold>(A)</bold> nitrite and <bold>(B)</bold> nitrate, and plasma <bold>(C)</bold> nitrite and <bold>(D)</bold> nitrate in 4-week-old global <italic>Xdh</italic> deleted mice and their wild type littermate controls. Levels of liver <bold>(E)</bold> nitrite and <bold>(F)</bold> nitrate, and plasma <bold>(G)</bold> nitrite and <bold>(H)</bold> nitrate in HXOR KO mice versus the <italic>Xdh<sup>fl/fl</sup></italic> wild type littermate controls. Nitrite reductase activity of liver homogenates at <bold>(I)</bold> pH 7.4, and <bold>(J)</bold> pH 6.8 and <bold>(K)</bold> plasma at pH 6.8 and <bold>(L)</bold> cGMP concentration of platelets isolated from blood samples collected from 4-week-old global <italic>Xdh</italic> deleted mice versus their wild type littermate controls. Nitrite reductase activity in liver homogenates, at <bold>(M)</bold> pH 7.4, and <bold>(N)</bold> pH 6.8 and <bold>(O)</bold> plasma at pH 6.8 <bold>(P)</bold> and cGMP concentration of platelets isolated from blood samples, collected from 20-week-old HXOR KO mice versus the <italic>Xdh<sup>m</sup></italic> wild type littermate controls. Data are shown as mean ±SEM of n mice (shown on individual graphs). Statistical significance was determined using one-way ANOVA followed by Sidak’s multiple post-tests highlighting significant difference from <italic>Xdh</italic><sup>+/+</sup> ì<bold>(A-D and L),</bold> using mixed effect analysis <bold>(E-H),</bold> two-way ANOVA <bold>(M-O)</bold> followed by Sidak’s I multiple <italic>post hoc</italic> tests shown as *P&lt;0.05, **P&lt;0.01, ***P&lt;0.001 vs <italic>Xdh<sup>+/+</sup></italic> or <italic>Xdh<sup>ff/fl</sup></italic> at) respective concentration, or unpaired Student’s t-test <bold>(L and P)</bold></p></caption><graphic xlink:href="EMS199926-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title><italic>Xdh<sup>+/-</sup></italic> and HXOR KO mice exhibit raised blood pressure.</title><p><bold>(A)</bold> Systolic, <bold>(B)</bold> diastolic, and <bold>(C)</bold> mean arterial pressure were raised in <italic>Xdh<sup>+/-</sup></italic> versus <italic>Xdh<sup>+/+</sup></italic> mice and <bold>(D-F)</bold> HXOR KO versus <italic>Xdh<sup>fl/fl</sup></italic> mice. Data are shown as mean ± SEM of n mice (shown on graphs <bold>(A)</bold> and <bold>(D)</bold>). Statistical significance w<sup>-</sup>as determined using mixed-effect analysis followed by Sidak’s multiple <italic>post hoc</italic> tests shown as *P&lt;0.05, **P&lt;0.01, ***P&lt;0.001.</p></caption><graphic xlink:href="EMS199926-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title><italic>Xdh<sup>+/-</sup></italic> and HXOR KO mice exhibit left ventricular remodelling.</title><p>Echocardiography data of <italic>Xdh<sup>+/-</sup></italic> versus <italic>Xdh<sup>+/+</sup></italic> littermates, at 8-16 weeks, and <italic>Xdh<sup>fl/fl</sup></italic> versus HXOR KO littermates at 10-20-weeks-old. <bold>(A)</bold> Short axis M-mode (SAX) LV corrected mass, and <bold>(B)</bold> parasternal long axis B-mode (PSLAX) acquisition of LV volume in diastole of <italic>Xdh<sup>+/-</sup></italic>versus <italic>Xdh<sup>+/+</sup></italic>littermates. <bold>(C)</bold> SAX LV corrected mass and <bold>(D)</bold> PSLAX LV volume in diastole of HXOR KO versus <italic>Xdh<sup>fl/fl</sup></italic>. <bold>(E)</bold> PSLAX LV area in diastole, <bold>(F)</bold> SAX LV internal diameter in diastole, <bold>(G)</bold> PSLAX LV area diastole, <bold>(H)</bold> SAX LV internal diameter in diastole, <bold>(I)</bold> SAX LV posterior wall thickness in diastole, <bold>(J)</bold> SAX heart rate, <bold>(K)</bold> SAX LV posterior wall thickness in diastole, <bold>(L)</bold> SAX heart rate, <bold>(M)</bold> SAX ejection fraction, <bold>(N)</bold> SAX stroke volume, <bold>(O)</bold> SAX ejection fraction, <bold>(P)</bold> SAX stroke volume, <bold>(Q and R</bold>) SAX cardiac output, and <bold>(S)</bold> dissected LV and tibia length from 20-week-old HXOR KO mice versus <italic>Xdh<sup>fl/fl</sup></italic> littermates. Data are shown as mean ±SEM of n mice (shown on graphs <bold>(A)</bold> and <bold>(C)</bold>). Statistical significance w <italic>^</italic>as determined using mixed-effects or Two-ANOVA analysis followed by Sidak’s multiple <italic>post hoc</italic> tests at an individual timepoint shown as *P&lt;0.05, **P&lt;0.01, ***P&lt;0.001.</p></caption><graphic xlink:href="EMS199926-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Upregulation of profibrotic pathways in <italic>Xdh<sup>+/-</sup></italic> and HXOR KO mice.</title><p><bold>(A)</bold> Representative images of picrosirius red (PSR) and wheat germ agglutinin staining (WGA) in sections of formalin fixed left ventricle (LV). Quantification of levels of <bold>(B, D)</bold> cardiac collagen deposition and <bold>(C, E)</bold> cardiomyocyte area in both the global <italic>Xdh<sup>+/-</sup></italic> and HXOR KO mice versus littermate controls. <bold>(F)</bold> Heatmap summary of all differentially expressed (DE) genes (q&lt;0.1) identified in total mRNA extracted from whole hearts of 8-week-old <italic>Xdh<sup>+/+</sup></italic> and <italic>Xdh<sup>+/-</sup></italic> mice. <bold>(G)</bold> Network plot demonstrating key disease and biological function annotations across DE genes. Longitudinal mRNA expression profiling in total mRNA extracted from whole hearts of <italic>Xdh<sup>+/-</sup></italic> and HXOR KO mice versus littermate controls investigating markers of fibrosis: <bold>(H, L)</bold> TGFβ, <bold>(I, M)</bold> SMAD2, <bold>(J, N)</bold> SMAD3, and <bold>(K, O)</bold> Col1a. Data are shown as mean ± SEM of n mice (shown on individual graphs). Statistical significance was determined using mixed effects analysis followed by Sidak’s multiple <italic>post</italic>- <italic>hoc</italic> tests. <bold>(D-E, H-O)</bold> or unpaired Student’s t-test <bold>(B, C).</bold> Uneven n values relate to sample loss due to technical failure or Routs exclusion.</p></caption><graphic xlink:href="EMS199926-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>HXOR KO and <italic>Xdh<sup>+/-</sup></italic>mice have impaired flow mediated dilatation (FMD).</title><p>FMD was assessed in both 20-week-old <bold>(A)</bold> <italic>Xdh<sup>+/-</sup></italic> and (<bold>D)</bold> HXOR KO mice versus littermate controls. An occlusion cuff placed above the left hind leg knee was inflated to 300 mmHg at T= 0 minutes to occlude blood flow through the left arteria iliaca externa. Time frame of occlusion is represented by the blue box. At T= 5 minutes the cuff was released (represented by the vertical dotted line). <bold>(B and E)</bold> show the maximal constriction of the vessel recorded during the occlusion phase expressed as a percentage change from the baseline diameter. The maximal FMD recorded post cuff release <bold>(C and F)</bold>. Data are shown as mean ± SEM of n mice (shown on individual graphs). Statistical significance was determined using two-way ANOVA followed by Sidak’s multiple <italic>post-hoc</italic> tests <bold>(A, D)</bold> with <bold>p</bold><italic>ost hoc</italic> test at an individual timepoint shown as *P&lt;0.05, or using unpaired Student’s t-test <bold>(B, C, E, F)</bold>.</p></caption><graphic xlink:href="EMS199926-f006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><title><italic>Xdh<sup>+/-</sup></italic> and HXOR KO mice exhibit elevated systemic inflammatory state.</title><p>Longitudinal TNFα mRNA expression in liver homogenate and plasma TNFα levels in 4-week-old of <italic>Xdh<sup>+/-</sup></italic> mice versus <italic>Xdh<sup>+/+</sup></italic> littermates (<bold>A-B)</bold> and HXOR KO mice versus <italic>Xdh<sup>fl/fl</sup></italic>littermates <bold>(C)</bold> and <bold>(D).</bold> Brightfield intravital microscopy was used to determine the number of <bold>(E and G)</bold> rolling and <bold>(F and H)</bold> adhering leukocytes in mesentery vessels of 4-5-week-old <italic>Xdh<sup>+/-</sup></italic>and HXOR versus wild type littermate mice. Representative images of CD62P staining (<bold>I</bold>) in vessels of liver and heart and their quantification <bold>(J and L)</bold> and <bold>(K and M)</bold> of <italic>Xdh<sup>+/-</sup></italic> and HXOR versus wild type littermate mice. Data are shown as mean ±SEM of n mice (shown on individual graphs). Statistical significance was determined using two-way ANOVA followed by Sidak’s multiple <italic>post-hoc</italic> tests <bold>(A, C, L, and M)</bold> or using unpaired Student’s t-test <bold>(B, D, F-K).</bold> Uneven n values relate to technical failure or exclusion using ROUTS.</p></caption><graphic xlink:href="EMS199926-f007"/></fig><fig id="F8" position="float"><label>Figure 8</label><caption><title>XOR enhances leukocyte recruitment under I/R injury, which is reduced with inorganic nitrate.</title><p>Brightfield intravital microscopy was used to visualise leukocyte <bold>(A)</bold> rolling and <bold>(B)</bold> in mesentery vessels following 30 minutes of localised ischemia and 45 minutes of reperfusion in 4-5-week-old <italic>Xdh<sup>+/-</sup></italic> versus wild type littermate mice. At 3-4 weeks of age drinking water was supplemented with either 15 mM KNO<sub>3</sub> (nitrate intervention) or 15 mM KCl (vehicle) for 1 week prior to I/R injury. At the end of the 1-week KNO<sub>3</sub>/KCl pretreatment I/R injury was induced, as previously stated and leukocyte <bold>(C)</bold> rolling and <bold>(D)</bold> adhesion was assessed. Data are shown as mean ± SEM of n mice (shown on individual graphs). Statistical significance was determined using Two-way ANOVA followed by Sidak’s multiple <italic>post-hoc</italic> tests.</p></caption><graphic xlink:href="EMS199926-f008"/></fig></floats-group></article>